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1.1 Genetic manipulation 
 
Genetic manipulation or genetic engineering is the ability to modify the behaviour 
of a gene or group of genes. In biological research, since nucleic acids were shown 
to be responsible for control of cellular functions and transfer of biological 
information, the urge to understand how genetic material works led to the 
development of tools in order to manipulate gene expression.   
By observing the phenotype of an organism upon enhancing, inhibiting or disrupting 
gene expression it is possible to understand how a gene works and how it 
influences a target organism.  
Transgenic or genetic modified organisms (GMO) are organisms that express 
genes originally expressed by different organisms. They are invaluable tools for 
research, agriculture, industrial and biomedical applications for they allow the 
generation of new research models and tools for production of important 
biomolecules such as hormones, drugs and enzymes. 
Transgenic animal models are key components on biomedical research. The 
advancements on understanding and treating genetic disorders on the past 
decades is due to the ability of mimicking genetic conditions on target organisms 
that would otherwise be impossible to be studied. However, the generation of 
transgenic or knock-out animal models, especially complex organisms such as non-
human primates is laborious, time consuming and expensive (Racay, 2002).  
The refinement and development of genetic manipulation techniques such as 
genome editing tools are thought to be the key for a new era of GMO production, 
leading to easier, more controlled alteration of gene expression on a genomic level.  
 
1.2 Gene therapy 
 
The generation of GMO led to a greater understanding of genetic diseases. 
Changes in the expression profile of a single gene or group of genes is the cause 




Gene therapy aims to try and correct dysfunctional genes by manipulation of their 
expression through transgene expression or gene expression suppression. For 
successful gene therapy, the correct foreign genes need to be delivered to the 
dysfunctional cells where they can be expressed and lead to an effect. There are 
several gene manipulation tools and gene delivery tools that have been developed 
and some of them are already in use in the clinics. These tools will be described in 
greater detail in this text. 
One of the greatest concerns regarding gene therapy in humans is the safety of the 
procedure. A lot of effort has been put on developing and improving gene 
engineering tools and gene delivery tools regarding their safety and efficiency. 
Several clinical trials have been performed with different degrees of success 
(Sheridan, 2011). The first reported gene therapy study was performed by Blaese 
and colleagues in 1990 aiming to rescue the expression of an enzyme (adenosine 
deaminase – ADA) in T cells, to limited success (Blaese et al., 1995). Ten years 
later, Cavazzana-Calvo and colleagues were able to replace a defective cytokine 
receptor subunit that prevented T and natural killer lymphocyte differentiation. Even 
though a causality was reported, that study was considered the first successful trial 
involving gene therapy (Cavazzana-Calvo, 2000). Since the 1990´s a variety of 





Figure 1. Number of approved clinical trials involving gene therapy in humans 
from 1989 to 2018. The development of new genetic manipulation and gene delivery 
tools led to a substantial increase in the number of approved gene therapy clinical trials 
worldwide. Source: The Journal of Gene Medicine. 
 
1.3 Genetic manipulation tools 
 
A genetic disorder can be caused by a single gene or pool of genes that are 
malfunctioning by either lack of expression or overexpression of its products. Gene 
therapy aims to correct the disfunctions by introducing specific transgenes that can 
replace, inhibit or activate a faulty gene function.  
1.3.1 Replacing dysfunctional genes: transgene expression cassettes 
 
A commercially available gene therapy treatment is sold under the name Glybera and 
aims to replace the function of a defective lipoprotein lipase (LPL) caused by a single-




Genetic disorders caused by a single gene or monogenic disorders such as 
haemophilia and muscular dystrophy are better understood and where the focus of 
most gene therapy trials to date have been put on. Most disorders are caused by lack 
of expression of a gene that can be counterfeited by insertion of a transgene 
expression cassette containing a copy of the faulty gene into the patient cells, usually 
in the form of a complementary DNA (cDNA) paired with a promoter. 
The choice of the promoter to drive transgene expression needs to be careful and lead 
to long term expression. For in vitro and some in vivo applications, viral-based 
promoters are widely used for they lead to strong expression of the transgene and 
have a reduced size, which facilitates its packing into delivery tools. The 
cytomegalovirus (CMV) promoter is one of the most common promoters used for 
transgene expression but it was shown to elicit a higher immune response to the 
transgene product and lead to a shorter-term expression (Papadakis et al., 2004), 
possibly because the mammalian cells evolved to detect and countereffect viral 
components.  
Eukaryotic-based promoters are a better choice when it comes to human gene therapy. 
They provide in general weaker transgene expression and have longer sequences 
when compared to viral promoters but allow for longer term expression. Furthermore, 
the possibility of tissue-specific promoters adds an additional layer of safety for the 
transgene expression can be directed to a population of cells.  
The elongation factor 1α (EF1α) and the human phosphoglycerate kinase 1 (PGK1) 
promoters are non-tissue specific promoters that were found to lead to the strongest 
transgene expressions when compared to CMV promoter (Fan et al., 2000), 
(Ramezani et al., 2000). The reduced size of EF1α promoter makes it an interesting 
choice for gene therapy. 
The use of a cell-specific promoter is indicated for gene therapy for a variety of studies 
showed that expression of transgenes in antigen presenting cells (APC) can lead to 
immune response (Hartigan-O’Connor et al., 2001), (Pastore et al., 1999), (Weeratna 
et al., 2001). Tissue-specific driven expression also leads to lower risks of cell toxicity 
and adverse effects caused by transgene expression. A comprehensive summary of 
tissue-specific promoters for use in gene therapy, including central nervous system 





1.3.2 Inhibiting gene expression at the post-translational level: RNA 
interference (RNAi) 
 
RNA interference methods allow for gene expression repression at the post-
translational level by interfering with messenger RNA (mRNA) biogenesis. The 
introduction of double-stranded RNA containing specific complementary sequences to 
target mRNAs can lead to inhibition of mRNA activity through cleavage of the complex 
by the RNA interference silencing ribonucleoprotein complex (RISC) (figure 6).  
In 1998 Fire and colleagues used double-stranded RNA (dsRNA) to drive strong gene 
silencing in the nematode Caenorhabditis elegans. They discovered that the silencing 
mechanism was due to the interaction of the antisense strand of the dsRNA with the 
complementary target mRNA (Fire et al., 1998).  The synthetic dsRNA is also known 
as small interfering RNA (siRNA). 
Short hairpin RNA (shRNA) are single-stranded RNA molecules that naturally form a 
hairpin like structure. These molecules are synthesised by RNA polymerase 3 and 
therefore need a vector containing a suitable promoter (such as U6) to be properly 
expressed in cells (Cullen, 2005). Both RNAi systems act by interaction with mRNA 
inhibiting the translation step.  
A commercially available treatment consisting of RNAi under the name Patisiran aims 
to treat hereditary transthyretin-mediated amyloidosis by decreasing the expression of 
transthyretin (TTR) and therefore the hepatic accumulation of misfolded TTR (Kristen 
et al., 2019). 
Although strong levels of gene silencing can be achieved through RNAi techniques, 
these tools are not without flaws. Off-target effects are an issue and therefore the target 
sequences need to be carefully chosen. The shRNA needs to be delivered as a 
construct in combination with a pol 3 suitable promoter, which is known to not allow for 







1.3.2.1 Gene silencing to study of biological function of new molecules 
 
The cytokine receptor-like factor 3 (CRLF3) is an orphan receptor whose function in 
mammalian organisms has yet to be uncovered. It is part of a family of receptors known 
to interact with type I cytokines.  
Erythropoietin (Epo) is a type I cytokine that increases the amount of red blood cells 
by inhibiting apoptosis (Fisher, 2003). Besides its classical role in erythropoiesis, Epo 
has been shown to also act on development of nervous tissue (Masuda et al., 1994), 
(Konishi et al., 1993) and induce neuroprotection (Morishita et al., 1996), (Sakanaka 
et al., 1998), (Brines et al., 2000).  
Leist and colleagues demonstrated that modified Epo molecules without hematopoietic 
activity were still able to drive protector effects through interactions with receptors other 
than the classic Epo receptor (EpoR) (Leist et al., 2004). The search for 
neuroprotective Epo receptors then began in invertebrates and in 2017 Hahn and 
colleagues showed that an insect ortholog of CRLF3 was involved in Epo mediated 
neuroprotection (Hahn et al., 2017). These findings bring the question of whether the 
human CRLF3 conserve the same function as its counterpart in insects. Gene silencing 
is a powerful tool to help answer questions regarding unknown biological functions of 
emergent molecules and therefore presents itself as a method to be utilised in order to 
better understand CRLF3 biology.  
1.3.3 Genome editing tools 
  
Targeted genome editing techniques take advantage of the ability of engineered 
nucleases to promote double-strand breaks (DSB) in the DNA molecule leading to 
activation of the DNA self-repair mechanism by homologous recombination allowing 
insertion of exogenous sequences or non-homologous end-joining, which can lead to 
small insertions or deletions and consequent loss of function mutations (González et 
al., 2014). It allows modifications in the genome such as insertions, replacement or 
removal of specific DNA sequences, thus enabling specific, controlled genome editing. 
The currently most used techniques are Zinc finger nucleases (ZFN), Transcription 
activator-like effector nucleases (TALENs) and Clustered regularly interspaced short 
palindromic repeats (CRISPR)/Cas9 (CRISPR associated nuclease 9). The latter 
system has attracted much attention on the past years for it is an extremely versatile 




1.3.3.1 Clustered regularly interspaced short palindromic repeats (CRISPR)-
Cas9 (CRISPR associated nuclease 9) 
 
CRISPR-Cas9 is a system derived from an RNA-guided eukaryotic defence system. It 
consists in a region of bacterial genome containing short DNA sequences copied from 
exogenous organisms such as virus and phages intercalated within palindromic 
repeats in the host genome. When associated with Cas endonucleases it acts as a 
primitive adaptative immune system (Mojica et al., 2005), (Pourcel et al., 2005).  
The specificity of the cleavage by Cas is driven by a CRISPR RNA (crRNA) transcribed 
from a locus in the CRISPR sequence which associates to a transactivating RNA 
(tracrRNA) to target invader organism’s genomes in a specific manner (Deltcheva et 
al., 2011). For a straight forward schematic of the system see figure 2. A simpler 
version of the system has been developed in which the complex crRNA+tracrRNA has 
been put together into a single guide RNA (sgRNA) (Gasiunas et al., 2012).  
Figure 2. Schematic view of the classic CRISPR-Cas9 system. Figure depicts the 
association of a CRISPR RNA (crRNA) with transactivating RNA (tracrRNA) to form a 
single guide RNA (sgRNA) which in combination with a nuclease Cas9 targets a 
specific genome sequence adjacent to a protospacer adjacent motif (PAM). The Cas9-
sgRNA complex leads to a specific DBS dictated by the sgRNA sequence 




In 2013 the first reports of successful translation of the prokaryotic system for use in 
human cells were published (Cong et al., 2013), (Mali et al., 2013a). Since then, 




application of the CRISPR system and overcome its disadvantages, such as off-target 
effects and possible immune response against Cas9 for in vivo applications. 
 
1.3.3.2 Further CRISPR applications: activation and inhibition of gene 
expression 
 
By preventing Cas9 from its nuclease activity, the utility of the CRISPR-Cas9 system 
can be further extended. Several studies describe a method to disrupt Cas9 nuclease 
activity, turning it into an RNA guided DNA binding protein (Qi et al., 2013),  (Mali et 
al., 2013b), (La Russa and Qi, 2015). By mutating its nuclease active domains, a 
nuclease- defective Cas9 or dead Cas9 (dCas9) was generated, see figure 3. 
 
 
Figure 3. Schematic view of nuclease-deactivated Cas9 (dCas9). Mutations on the 
nuclease activity domain of Cas9 leads to a molecule incapable of inducing DSB. The 
protein will still interact with an sgRNA and be targeted to a specific genomic region 
where it will sit and diminish the availability of this region to the transcription machinery. 
Source: (La Russa and Qi, 2015). 
 
The new dCas9 protein can be used as a transcription factor-like molecule. By 
appending factors to dCas9 the transcription machinery can be attracted to a specific 
promoter region activating gene transcription. This method is known as CRISPR 
activation or CRISPRa.   
Several studies report fusing different activators to dCas9 in order to achieve enhanced 




VPR) for stronger effect. See (Mali et al., 2013b), (Gilbert et al., 2013),  (Maeder et al., 
2013), (Perez-Pinera et al., 2013), (Tanenbaum et al., 2014), (Chavez et al., 2014), 
(Konermann et al., 2015). 
Additionally, dCas9 can be fused to transcription inhibitors factors that once driven to 
a promoter genomic region will prevent the transcription machinery to reach a specific 
gene, leading to gene repression. This method is known as CRISPR interference or 
CRISPRi. Although it has been shown that dcas9 alone when guided to DNA can 
decrease gene expression (Gilbert et al., 2013), (Qi et al., 2013), when inhibitor factors 
are fused to dCas9 the repression efficiency is more accentuated (Konermann et al., 
2013), (Gilbert et al., 2014). 
 
1.4 Gene delivery tools 
 
All gene manipulation techniques described above have a common treat: the necessity 
of expression of a foreign gene in the target cell. To do so, gene delivery tools that can 
effectively deliver the desired genetic material into the adequate systems are 
necessary. 
The most used techniques to insert transgenes into organisms in vitro are physical 
techniques such as electroporation, where a brief electric current will open pores on 
the cell wall or membrane allowing the diffusion of genetic material into the cell. 
Chemical methods based on cationic lipids and DNA precipitation with salts are also 
commonly used for they are simple to use and effective. 
 
1.4.1 Gene delivery tools: viral vectors 
   
When it comes to in vivo and gene therapy applications, these methods prove to be 
inadequate due to difficulty of assessment of targeted regions and possible toxicity. 
Viral vectors are the tool of choice because they exploit the natural role of viral particles 
as organisms that invade and use cell machinery for replication of their genetic 
material.  
Adenoviruses (Ad), adeno-associated viruses (AAV), retroviruses and lentiviruses (LV) 




have been engineered to be replication deficient and deliver solely the gene of interest 
(GOI) into host cells.  Every viral type has its own applications, depending on which 
organisms they can transduce, the packaging limit, if it can transduce dividing or non-
dividing cells, if it elicits an immune response among others. 
All the afore mentioned viral vectors are currently being tested or have been tested on 
clinical trials. For an overview on which viruses are being used for different clinical 
purposes, see (Sheridan, 2011). For the purposes of this thesis LV and AAV will be 
described in greater details. 
 
1.4.1.1 Viral vectors: Lentiviruses 
 
Lentiviruses are enveloped single-stranded RNA viruses from the Retroviridae family. 
Once inside the host cell the viral genome is reverse transcribed through a reverse 
transcriptase enzyme producing cDNA that can be integrated into the host genome. 
Several LV are mammalian pathogens known to cause immunodeficiency-like 
diseases i.e. Simian immunodeficiency virus (SIV), Feline immunodeficiency virus 
(FIV) and human immunodeficiency virus (HIV).  
HIV is an important pathogen that causes an acquired immunodeficiency syndrome 
(AIDS) in humans by targeting immune cells such as CD4+, macrophages and 
dendritic cells. There are two main subtypes known as HIV-1, the most common and 
virulent and HIV-2, restricted to Africa and with apparent lower virulence.  
Since the outbreak of AIDS in the early 1980s, extensive research efforts have been 
made in order to understand HIV biology. Although there is no cure for HIV infection to 
date, those efforts were crucial for the development of prevention strategies and 
treatment programs, as well as the advent of utilizing the virus as a biotechnological 
tool that could be used in researches advantage. 
The genome of the virus is comprised of several genes for expression of structural viral 
elements as well as enzymes and products for nuclear trafficking, which allows the 
viral genes to be transported into the cell nuclei. These genes are flanked by 5´and 3´ 
long terminal repeats (LTR) regions which act as promoter for viral gene expression 
and polyadenylation and contains a packaging signal to drive encapsulation of newly 





Figure 4. Typical lentiviral particle. Scheme shows the main viral components and 
the viral genes responsible for expression. Lentivirus are around 80-100nm in 
diameter. When shedding from the host cell they are coated with a patch of membrane 
that will become the viral envelope and determine viral tropism. Adapted from 
https://library.med.utah.edu/WebPath/TUTORIAL/AIDS/AIDS004.html  
 
1.4.1.2 Lentiviruses and gene therapy 
 
As research tools for gene delivery, SIV, FIV and HIV-1 based viral particles have been 
engineered to deliver genes of interest into host cells in a controlled and safer manner 
when compared to their wt versions.  
HIV-1 based LV are efficient gene delivery tools for both in vitro and in vivo gene 
therapy. The main advantages of this system are rooted in the biology of the virus itself: 
the ability to infect non-dividing cells which makes them useful tools for neurosciences 
applications; 
• The fact that the viral genome is integrated into the host genome, leading to 
long term, stable transgene expression; 
• The high yields of viral particles by producer cells; 
• The relatively high packing capacity in the range of ~8.5kb which allows for the 
incorporation of longer constructs consisting of an adequate promoter and GOI; 
• The possibility of altering the viral tropism by manipulating the expression of 
proteins on the viral envelope (figure 4). 
Perhaps the most striking feature of HIV based LV is the straightforward manipulation 




of the cell membrane that will become the viral envelope. The tropism of the viruses is 
dictated by the molecules expressed on the envelope (figure 4). Pseudotyping LV is a 
procedure by which glycoproteins from other virus types are incorporated into the LV 
envelope, providing the new viral particles with the targeting affinity of the original virus 
type. The vesicular stomatitis virus glycoprotein (VSV-G) is widely used to pseudotype 
LV for research purposes. It gives rise to viral particles with a broad tropism, greatly 
increasing viral transduction efficiency.  
The use of a pathogenic virus such as HIV as vectors for gene therapy is of course 
source of concern. On the past decades HIV was thoroughly studied and the role of 
each component from the viral genome was assessed.  
Nowadays, only three out of nine wt HIV genes are present in constructs used to 
produce pseudotyped LV: gag, rev and pol responsible for expression of the viral 
capsid, nuclear export element and viral enzymes (reverse transcriptase and 
integrase), respectively (figure 5).  
 
 
Figure 5. Schematic representation of HIV genome and packaging construct. 
Upper panel shows wt viral genome flanked by the two long terminal repeat (LTR) 
regions. On modern LV expression cassettes only gag, pol and rev are present under 
expression of a constitutive promoter (CMV) lower panel. Source: (Naldini et al., 1996) 
   
 
Zufferey and colleagues (Zufferey et al., 1998) further improved the LV system by 




lead to viruses that will deliver a GOI and will not enter a replication cycle inside the 
cell.   
HIV-1 based pseudotyped viruses are produced in high protein producing cell lines 
modified to express a Simian vacuolating virus (SV40) large T antigen (Ali and 
DeCaprio, 2001) by transient transfection of plasmids containing viral components 
(gag, pol, rev), GOI flanked by LTR and an envelope protein (second generation 
method). Advancing a step further regarding the safety of the system, third generation 
lentiviral production method separates the rev element in another plasmid. This 
decreases the chances of viral components recombination. New viral particles bud 
from the producer cells carrying a patch of the cell membrane as envelope and are 
secreted into the culture medium. Supernatant containing viral particles can be used 
directly for transduction after clarification by centrifugation and filtration. Additionally, 
the SN can be concentrated to increase the viral titer and facilitate inoculation into 
organisms.   
In 2003 Carl June and colleagues (Levine et al., 2006) performed the first clinical trial 
using HIV-1 based LV for gene therapy. Ironically the target of the trials was the 
treatment of chronic HIV infected patients. The subjects had CD4+ cells treated ex vivo 
with LV containing an antisense gene against wt HIV envelope. The cells were later 
reinfused into the patients.  Immune function improved in four out of five subjects. Other 
clinical trials using LV for gene therapy followed including a β-thalassemia treatment 
(Thompson et al., 2016) and Parkinson´s disease (Palfi et al., 2014) (Palfi et al., 2018) 
showing that although in need of efficiency improvements, the LV system is safe for 
use in patients.  
 
1.4.2 Viral vectors: Adeno-associated viruses 
  
Adeno-associated virus (AAV) are single-stranded DNA viruses from the Parvoviridae 
family. They are small non-enveloped particles (20-25nM) that are not known to be 
pathogenic. To date twelve different human AAV serotypes have been reported (AAV-
1 to AAV-12). Its replication is dependent on co-infection with other viruses such as 
adenoviruses (Carter, 2004).  
AAVs are widely used in gene therapy for they can transduce non-dividing cells, have 




absence of associated viruses (Naso et al., 2017). Since the first clinical trial in the 
early 1990s involving AAV by Flotte and colleagues (Flotte et al., 2008), a number of 
studies were published on the subject (Carter, 2004). Recently, positive effects on AAV 
efficiency were reported upon association with extracellular vesicles, namely 
exosomes (Maguire et al., 2012). The so called exo-AAV are an interesting new tool 
for gene therapy, because in theory these particles can be pseudotyped by altering the 
molecules expressed by the exosomes.     
 
 
1.5 Gene expression regulation: the small nucleolar RNA U3 and micro RNA 
biogenesis 
 
microRNA (miRNA) are small non-coding RNA composed of 22nt that play a role in 
mRNA expression regulation. They are abundant in the in the mammalian cell and are 
also present in plants and even viruses. Their biogenesis is regulated by an intricated 
machinery that starts in the nuclei and ends the process in the cytoplasm. Notably in 
the nucleus the nascent miRNA molecule is processed by Drosha and DGCR8 and 
then exported to the cytoplasm by Exportin-5 (XPO5), where it is further cleaved by a 














Figure 6. Simplified view of miRNA biogenesis pathway. Schematic depiction of 
miRNA biogenesis from transcription by Polymerase II and processing by Drosha in 
the nucleus. Upon transport to the cytosol by Exportin-5 (Exp5) the pre-miRNA is 
further processed by Dicer. Source: (Cullen, 2005) 
 
Small nucleolar RNA (snoRNA) are small RNA molecules that are believed to be 
exclusively in the nuclei where it participates in ribosomal biogenesis (Bachellerie et 
al., 2002) (Watkins et al., 2007). U3 is a snoRNA that is independently transcribed and 
unlike other snoRNA is believed to localize exclusively in the nucleus (Cléry et al., 
2007). However, some studies suggested the processing of snoRNA into miRNA 
(Ender et al., 2008), (Brameier et al., 2011), which would require cytosolic presence of 
snoRNA.  
Dr. Nicolás Lemus, during his PhD studies, found strong evidence that the 5´domain 
of snoRNA U3 may indeed be further processed into a functional miRNA.  Through 
NGS data analysis it was found out that U3-derived miRNA interacts with microRNA 
ribonucleoprotein complex (miRNP), which indicates processing into miRNA. Also, 




at a single cell level (Lemus-Diaz et al., 2017), it was shown that snoRNA U3 derived 
miRNA may play a role as a functional miRNA (figure 7).  
 
 
Figure 7. Dual fluorescence assay for assessment of miRNA functionality at 
single-cell level. Cells are transfected with a dual fluorescence construct for 
expression of yellow fluorescent protein (YFP) and cyan fluorescent protein (CFP) 
(Lemus-Diaz et al., 2018). On CFP 3´untranslated region a small complementary 
miRNA sequence is fused. Upon binding of fitting endogenous miRNA, translation of 
CFP is diminished, while YFP is not affected and remains constant, as a control. 
Fluorescence is analysed by fluorescence-activated cell sorting (FACS). Three 
different U3 sequences were used and the effects of fusing one or three copies of the 
same sequence were analysed. Red dots represent the effects of three copies of U3 
complementary sequences on CFP expression. Decreased CFP expression indicates 












1.6 Aim of the thesis 
 
Genetic manipulation is a powerful tool for biological research and the clinics. The 
improvement and development of gene manipulation techniques as well as gene 
delivery tools is crucial for the success and advancements of the field. 
In this thesis, we aimed to produce gene delivery tools that are more specific and 
efficient on delivering a gene of interest.  
We also aimed to utilise our delivery tools to test effective gene manipulation 
techniques to assist us on answering interesting scientific questions: 
Is the CRLF3 receptor linked to Epo mediated neuroprotection in mammals? 
























2. Materials and Methods 
 
2.1. Molecular biology 
 
All buffers and media compositions are listed on table 8. A list of vectors used for 
cloning and LV production can be found on tables 5 and 6. Plasmid maps are shown 
in the Appendix section.  
2.1.1. Plasmid restriction 
 
DNA constructs were digested using appropriate restriction enzymes from New 
England Biolabs (USA) or Thermo Fisher Scientific (Germany) according to 
manufacturer´s instructions. In brief, plasmids were mixed with appropriated buffers, 
purified H2O and enzymes and incubated at 37°C for at least 1h or overnight when 
there was no star activity described for the enzyme. 
2.1.2. Electrophoretic DNA fragment separation and documentation 
 
Digested constructs were mixed with 6X DNA loading dye (Thermo Fisher Scientific, 
Germany) and 10µL were loaded into a 1 or 2% w/v Agarose gel (Carl Roth, Germany). 
DNA fragments were separated by applying 130V for 45min in TAE buffer. Bands were 
visualized by incubation in Ethidium bromide staining 10µg/mL in H2O (Carl Roth, 
Germany) for 15min. DNA bands were documented on an INTAS Ge liX20 Imager 
(INTAS, Germany) under UV light.  
2.1.3. DNA gel purification 
 
Digested DNA fragments or PCR products were excised from the agarose gel with a 
clean scalp. Gel purification was carried out using a QIAquick Gel Extraction Kit 
(QIAGEN, Germany). Agarose gel slices were melted at 50°C with appropriate buffer 
under agitation for 10min according to manufacturer´s instructions. DNA content of 
purified products was obtained by spectrometry on a Synergy 2 Multi-Mode Microplate 
reader (BioTek, USA) using H2O as blank. Purified DNA was stored at -20°C.   
2.1.4. DNA ligation 
 
DNA fragments were ligated with T4 DNA ligase (New England Biolabs, USA) 




T4 DNA ligase buffer, purified H2O and ligase and incubated for 10min at room 
temperature or at 16°C overnight. 
2.1.5. Chemically competent cells expansion 
 
Competent E. coli were expanded using the Mix & Go! E. coli Transformation Kit (Zymo 
Research, Germany) according to manufacturer’s protocol. In brief, competent bacteria 
were inoculated in appropriate buffer and incubated t 37°C under agitation of 180rpm 
overnight. Cells were harvested by centrifugation, aliquoted and stored at -80°C.  
2.1.6. Bacterial transformation  
 
One Shot TOP10 chemically competent E. coli or One Shot Stbl3 Chemically 
competent cells were thawed on ice for 10min and 1-5µL plasmid or ligation product 
was added. The transformation reaction was incubated on ice for 5min and 
transformed bacteria were inoculated on a LB-agar plate with either 100µg/mL 
Ampicillin (Carl Roth, Germany) or 50µg/mL Kanamycin (Applichem, Germany). For 
plasmids conferring Kanamycin resistance, an additional step was performed after 
incubation on ice: 400µL of SOC medium was added and cells were incubated for 
30min at 37°C under mild agitation before being inoculated. Inoculated LB-agar plates 
were incubated at 37°C overnight.  
2.1.7. DNA extraction 
 
Individual bacterial colonies grown on LB-agar plates were picked with a sterile 
micropipette tip (Sarstedt, Germany) and transferred to tubes or flasks containing 
appropriate amounts of LB medium with appropriate antibiotic. Tubes were then 
incubated at 37°C for at least 8h under 180rpm agitation.   
2.1.7.1. DNA minipreps 
 
Bacterial suspension (2mL) were centrifuged on a Heraeus Fresco21 microcentrifuge 
(Thermo Fisher scientific, USA) at 15.000xg for 1min. Bacterial pellet was resuspended 
in 200µL by agitation with buffer P1 containing 100µg/mL RNAse (Sigma Aldrich, 
USA). 200µL of a mixture of buffer P2a+P2b was added and the contents mixed. 200µL 
of buffer P3 was added and the tubes were centrifuged at 15.000xg at 4°C for 10min. 




Isopropanol (Carl Roth, Germany) was added. The contents were centrifuged at 
15.000xg at 4°C for 30min. Supernatant was discarded, and DNA pellet was washed 
with 70% Ethanol v/v. Pellets were spun down at 12.000xg at 4°C for 15min. 
Supernatant was discarded, and pellets could air dry and later be resuspended in 50µL 
purified H2O and stored at -20°C. 
2.1.7.2. DNA midipreps 
 
DNA midipreps were prepared using a ZymoPURE Plasmid Midiprep Kit (Zymo 
Research, Germany) according to manufacturer’s instructions. The extracted DNA was 
column purified and eluted with 200µL purified H2O. Minipreps were stored at -20°C. 
2.1.8. Polymerase chain reaction 
  
PCR reactions were carried out using appropriate primers synthesized by Sigma 
Aldrich (Germany). Either Taq DNA polymerase (Biotherm, Germany) or Phusion High-
fidelity DNA Polymerase (Thermo Fisher Scientific, Germany). The protocols and 
thermocycling programs were adjusted for each reaction, but general protocols for the 
PCR reaction mix and cycling program are described in table 1 and 2 respectively.  
Table 1: PCR reaction mix general protocol 
Component Volume 
  Taq Phusion 
DNA template (50-100ng) XµL (100ng) XµL (50ng) 
Reaction buffer (5-10X) 3µL (10X) 4µL (5X) 
dNTPs (10mM) 0.2µL 0.4µL 
Forward primer (10µM) 1µL 1µL 
Reverse primer (10µM) 1µL 1µL 
Polymerase 0.2µL 0,2µL 
RNAse free H2O up to 30µL up to 20µL 
DMSO NA 0.6µL 
TOTAL 30µL 20µL 
 
PCR reactions were performed on a thermocycler Labcycler (Sensoquest, Germany) 






Table 2: General cycling conditions for PCR reactions 
  Taq Phusion   
Cycle step Temperature Time Temperature Time Cycles 
Initial 
denaturation 
95°C 5min 98°C 30s 1 
Denaturation 95°C 1min 98°C 5-10s 
30 Annealing 56°C 1min ≤69°C 10-30s 
Extension 72°C 1min 72°C 15-30s/kb 
Final extension 72°C 2min 72°C 5-10min 1 
Hold 4°C ∞ 4°C ∞ NA 
 
 
2.1.9. RNA isolation and cDNA synthesis 
 
Culture medium was discarded, and cells were homogenized with Trizol reagent 
(Thermo Fisher Scientific, USA). Total RNA was isolated according to manufacturer’s 
instructions. Isolated RNA was resuspended in RNAse free H2O and quantified on an 
Eppendorf BioSpectrometer basic (Eppendorf, Germany). Total RNA was reverse 
transcribed using the Sensifast cDNA Synthesis Kit (Bioline, UK) using 1000ng of total 
RNA. cDNA was stored at -20°C. 
2.1.10. Quantitative PCR 
 
In general, 20ng of cDNA template was used for qPCR on an ABI StepOnePlus system 
(Applied Biosystems, USA) using a SensiMix SYBR Hi-ROX Kit (Bioline, UK) according 
to manufacturer´s protocol. Relative quantification was calculated through ∆∆Ct 
method using the StepOnePlus Systems software (Applied Biosystems, USA). GAPDH 
and β2M expression were used as controls. A list of primers and sequences can be 
found in table 3. Comparison between nuclear and cytoplasmic expression of U3, U6, 
GAPDH and U1 was assessed as “fraction of total“ by determining the square of the 
Ct values of fractions subtracted from Ct values of total RNA. 





Total RNA was reverse transcribed using the miRCURY LNA RT Kit (QIAGEN, 
Germany) according to manufacturer’s instructions and obtained cDNA was used for 
LNA miRNA expression detection using a miRCURY LNA SYBR Green PCR Kit 
(QIAGEN, Germany) on an ABI StepOnePlus system (Applied Biosystems, USA). 
Relative expression was calculated by ΔΔCt-method using U6 as reference. Resulting 
amplified sequences were visualized by electrophoresis using the E-Gel Precast 
Agarose Electrophoresis System (Thermo Fischer Scientific, USA) in a 4% E-Gel 
Precast Agarose Gel. Probes complementary to targets U3, U6 and miR-34a were 






Table 3: Primer sequences used for PCR and qPCR 
Primer Purpose Sequence 
β2M forward Housekeeping 
TGTGCTCGCGCTACTCTCTCT 
β2M reverse CGGATGGATGAAACCCAGACA 
 
GAPDH forward Housekeeping 
AGGTCGGAGTCAACGGAT 
GAPDH reverse TCCTGGAAGATGGTGATG 
 
TrkB forward TrkB expression quantification 
GGGACACCACGAACAGAAGT 














CRLF3 reverse GCGCAGACTCTGAACTGGTA  
 
Her2/neu out 




























CRLF3 out forward CRLF3 cloning GTCGACATGAGGGGGGCGATGGAGCT 






















2.1.12. Cell fractionation and RNA extraction 
 
Cytoplasmic and nuclear RNA fractions were obtained using a Cytoplasmic & Nuclear 
RNA Purification Kit (Norgen Biotek Corp., Canada) according to manufacturer’s 
instructions. RNA was eluted from purification columns and quantified on an Eppendorf 
BioSpectrometer basic (Eppendorf, Germany). RNA samples were kept at -80°C.  
 
2.2. Cell biology 
 
2.2.1. Cell culture 
 
All cell lines were kept under standard conditions in humidified incubator at 37°C and 
5% CO2. For routine maintenance cells were harvested with Trypsin 0.05 %/EDTA 0.02 
% in PBS, w/o: Ca and Mg (PAN Biotech, Germany) and split accordingly. Cell lines 
and their respective culture media and supplements are summarized in table 4. 
HCT116 cells and knock-out variants were obtained from Korean Collection for Type 
Cultures (KCTC) KCTC-No BP1230983 to BP1230988 where they were deposited by 
Narry Kim (Kim et al., 2016). HEK293FT were purchased from Thermo Fisher 
Scientific, USA. All other cell lines were obtained from the American type culture 
collection – ATCC.  
2.2.2. Rat brain cortex dissociated culture 
 
Wistar rat brains were obtained from Markus Stahlberg (Trans-synaptic Signaling 
group – European Neuroscience Institute, Göttingen) in ice cold OptiMEM (Thermo 
Fisher Scientific, USA). Brains were processed as soon as possible by removing the 
meninges and isolating the cortex with appropriate tweezers. Isolated cortex was then 
sliced in small pieces with Surgical Disposable Scalpels (Braun, USA) and digested 
with Trypsin/EDTA solution (PAN Biotech) for 45min at 37°C. Digested tissue was 
gently dissociated by several passages through disposable pipette tips (Sarstedt, 
Germany) in DMEM supplemented with 10% heat inactivated FCS (Thermo Fisher 
Scientific, USA), 1% Penicillin/streptomycin and GlutaMAX-I (Thermo Fisher Scientific, 
USA). The cell suspension obtained was then seeded in 24-well plates containing 
glass cover-slips coated with 0,5% polyethylenimine (PEI) (Sigma Aldrich, Germany). 




supplemented with100mM GlutaMAX-I, 10.000U Penicillin+10mg Streptomycin/mL 




























2.2.3. Macaca fascicularis brain cortex organotypic culture 
 
Macaca fascicularis brains were obtained from the Infection Biology group from the 
German Primate Center in Göttingen, Germany in ice cold OptiMEM (Thermo Fisher 
Scientific, USA). Brains were processed as soon as possible by removing the 
Table 4: Cell lines, culture media and supplements 
Cell lines Media Supplement Provider 
HEK293 DMEM 10%FCS ATCC CRL-1573  
HEK293FT DMEM 
10%FCS + 1mM 
sodium pyruvate + 
1mM L-glutamine + 





Hela RPMI 10%FCS ATCC CCL-2  
SH-SY5Y DMEM-F12 10%FCS ATCC CRL-2266  
Raji RPMI 10%FCS ATCC CCL-86  




SKBR3 DMEM 10%FCS ATCC HTB-30 
MCF7 DMEM 10%FCS ATCC HTB-22  








* All media and supplements were manufactured by 
Thermo Fisher Scientific, USA  




meninges and isolating the cortex with appropriate tweezers. Slices 300μm thick were 
obtained by using a tissue slicer (Stoelting, Germany) equipped with double edges 
razor blades (Astra, Italy). Slices were kept in HBSS - Hank’s Balanced Salt solution 
(Thermo Fisher Scientific, USA) supplemented with 10mM HEPES (Carl Roth, 
Germany) and 5mg/mL Glucose (Carl Roth, Germany) during slicing process. 
Afterwards, cortex slices were laid onto filter membranes – cell culture inserts (Millicel 
– Millipore, USA) and transferred to 6-well culture plates in a way that the slices would 
be in contact with atmospheric air on the top and with the medium, without soaking, on 
the bottom. Three slices were kept in each filter membrane. Medium used was a 
mixture of the following components: 50% Minimun Essential Media (Thermo Fisher 
Scientific, USA), 25% HBSS (Thermo Fisher Scientific, USA), 25% FBS (Thermo 
Fisher Scientific, USA), 1% GlutaMAX-I (Thermo Fisher Scientific, USA), 1% 
Penicillin/streptomycin (PAN Biotech, Germany) and 5mg/mL Glucose. Medium was 
changed every 48 hours. All animal handling was carried out in accordance to 
approved ethical protocols.  
 
2.2.4. Fluorescence microscopy 
 
All fluorescent images were acquired in an Axio Vert.A1 epifluorescence microscope 
equipped with a blue LED for GFP excitation, a green LED for RFP excitation, an 





















Table 5: Plasmid vectors used for cloning 
Vector Description Function Origin 
pDisplay Mammalian expression 
vector that allows display 
of proteins on the cell 
surface. Proteins 
expressed from pDisplay 
are fused at the N-
terminus to the murine Ig 
κ-chain leader sequence, 
which directs the protein to 
the secretory pathway, and 
at the C-terminus to the 
platelet derived growth 
factor receptor (PDGFR) 
transmembrane domain, 
which anchors the protein 
to the plasma membrane, 






on the cell 
membrane 
Gift from Dr. Michael Winkler 
(Infection Biology Unit - 





Expresses S. pyogenes 
CRISPR chimeric RNA 
element with customizable 
sgRNA from U6 promoter 
and puromycin resistance 









Gift from Feng Zhang 






3rd gen lentiviral backbone 
for cloning and expression 
of new shRNA sequences. 









Gift from Bob Weinberg 








Construct for expression of 







Gift from Dr. Stefan 
Schneider (Infection Biology 










2.2.5. Lentivirus production 
 
HEK293FT cells were passaged 2 to 4 times prior to use. Only cultures with viability 
higher than 90% were used. Each experimental unit correspond to a 75cm2 cell culture 
flask (Sarstedt, Germany) containing initially 8,5x106 viable HEK293FT cells. 
Day 1: DNA constructs amounts used for co-transfection of viral components, GOI and 
envelope protein were calculated based on the molar fraction represent in the mix 
according to their lengths in base-pairs (bp). For each experimental unit, a total amount 
of 30μg of DNA was mixed with 300µL 2.5M CaCl2 (Carl Roth, Germany) in a 50mL 
Cellstar tube (Greiner Bio-one) and sterile H2O up to 1500µL. Afterwards, 1500µL 2X 
HEPES buffered saline was added and the contents bubbled 15 times with a 5mL 
serological pipette (Sarstedt, Germany). The solution was incubated at room 
temperature for 20min to allow calcium phosphate formation. In the meanwhile, 
HEK293FT cells seeded previously were detached, counted in a Neubauer improved 
chamber (Superior Marienfeld, Germany) and a suspension containing 8,5x105 cells/mL 
was prepared. 10mL of this suspension was added to 75cm2 culture flasks for each 
experimental unit. DNA-calcium phosphate mix was added slowly to the cells in 
suspension and mixed well. Cells were then incubated under standard conditions over 
night. The plasmids used for LV production are listed in table 6. 
Day 2: From this step on all procedures were carried out under S2 lab safety 
conditions. Any material/surface that might have had contact with infective material 
was rinsed with Optisept 7% (Dr. Schuemacher, Germany) before proper discarding. 
Since the GOI constructs contained either GFP or RFP transfection efficiency could be 
evaluated through fluorescence microscopy. Only experimental units showing 80% or 
more fluorescent cells (qualitative analysis) were used for further steps. The 
supernatant from each flask was collected to a 50mL tube and stored at 4°C. Fresh 
HEK293FT keeping medium (see table 4) supplemented with 10mM Sodium butyrate 
(Sigma-Aldrich, Germany) were added to the flasks. After 8h of incubation, the 
supernatant containing sodium butyrate was transferred to the corresponding tube 
containing the supernatant recovered before and stored at 4°C. Fresh HEK293FT 
medium was added to each flask. 
Day 3 and 4: The supernatant containing the viral particles was recovered and 
transferred to the corresponding tubes with supernatant from the day before. Fresh 




Day 5: The supernatant containing viral particles was collected from the flasks and 
transferred to the corresponding tubes. The pool of viral containing SN was centrifuged 
at 2000xg for 15min at 4°C on a Heraeus Megafuge 8R (Thermo Fisher Scientific, 
USA). The cleared supernatant was filtered through a 0.45µm Minisart NML Syringe 
Filter (Sartorius Stedim Biotech, Germany) into a fresh 50mL tube and kept at 4°C. 
 
 
2.2.6. Concentration of lentiviral particles 
 
20mL viral SN were added to Vivaspin 20 centrifugal concentrator - MWCO 30 kDa 
(Thermo Fisher Scientific, USA) and centrifuged at maximum speed at 4°C for 60min. 
The final volume obtained was around 200μL and was transferred to cryotubes and 
stored at -80°C. 
 
Table 6: Plasmids used for lentiviral production 
Vector Description Function Origin 
psPAX2 2nd generation 
lentiviral 
packaging 
plasmid. Can be 






Expression of viral 
structural 
components. 
Contains gag, pol 
and rev 
Gift from Didier Trono 













Expression of VSV-G 
on viral envelope 
 
Gift from Bob Weinberg 
(Addgene plasmid # 8454 ; 
http://n2t.net/addgene:8454 ; 
RRID:Addgene_8454) 






Contains GFP as 
GOI flanked by LTR 
driven by CMV 
promoter. Drive 
expression of GFP 
on transduced cells 
Gift from Eric Campeau & 
Paul Kaufman (Addgene 
plasmid # 17447 ; 
http://n2t.net/addgene:17447 
; RRID:Addgene_17447) 
pLemiR-NS Lentiviral shRNA 
expression 
plasmid. Contains 
Turbo RFP as 
reporter gene  
Puromycin 
resistence. 
Contains Turbo RFP 
and a non-specific 
shRNA as GOI 
flanked by LTR . 
Drive expression of 
RFP on transduced 
cells 
Gift from Jerry Crabtree 












expression on viral 
envelope.  
Gift from Miguel Sena-













Drives expression of 
a fusogenic molecule 
on the plasma 
membrane under 
CMV promoter 
Construct was generated on 
previous study: Lentiviral re-
targeting for in vivo neuro-
optogenetics applications. 
Rafael Rinaldi Ferreira 
Master´s thesis 
pDisplay-scFvTrkB A scFv-TrkB was 




for expression on 
cell membrane 
Envelope plasmid. 
Drives expression of 
svFv-TrkB on viral 
envelope. 
Construct was generated on 
previous study: Lentiviral re-
targeting for in vivo neuro-
optogenetics applications. 
Rafael Rinaldi Ferreira 
Master´s thesis 
pDisplay-scFv-Her2/neu A scFv-Her2/neu 








Drives expression of 
svFv-Her2/neu on 
viral envelope. 
scFv-Her2/neu was cloned 
from pPICZαA-Her2neu-














CRLF3 as GOI 
flanked by LTR 
driven by U6 
promoter 
 
shRNA against CRLF3 
was cloned into the 
pLKO.1 Puro vector 
 
 
2.2.6. Flow cytometry 
 
Cells were harvested with Trypsin-EDTA and centrifuged at 500xg for 5min. Cell pellets 
were washed twice with 1mL 1X PBS (PAN Biotech, Germany) and incubated with 2% 
paraformaldehyde in PBS (Carl Roth) for 30min at 4°C for fixation. After centrifugation 
cell pellets were washed three times and resuspended in 200µL PBS and transferred 
to 5mL Falcon Round-Bottom Polypropylene Tubes (Omnilab, Germany). Cell 
suspensions were analysed on a BD LSR II flow cytometer (BD Biosciences, USA) 




Fluorescence was detected using PE 550LP- BP575/26 filter set for RFP and 505LP - 
BP530/30 filter set for GFP detection. Data was analysed using the Flowing Software 2 
and GraphPad Prism 6. 
 
2.2.6.1. Functional lentivirus titer 
 
Functional LV titer was assessed according to (Kutner et al., 2009). In brief, cells were 
seeded in 24-well plates and transduced with serial dilutions of viral supernatant or 
concentrated viral SN. They were harvested 48-72h after and prepared for FACS 
analyses as described in section 2.6.6.  10.000 events were acquired per sample and 
gates were applied in order to exclude populations of cells showing aberrant 
fluorescence intensity and size. Non-transduced cells were used as negative control. 
The final data obtained were expressed as percentage of fluorescent cells per sample. 
 
Data was analysed using Microsoft Excel 2010 software (Microsoft Corporation). 
Functional titer was calculated as the average amount of transducive units (TU) per 
mL using the following formula: TU = (F x N x D x 1000) / V, where F = percentage of 
fluorescent cells, N = number of cells at the time of transduction, D = fold dilution of 
vector sample used for transduction and V = volume (μL) of diluted vector sample 
added into each well for transduction. 
 
2.2.7. Lentivirus physical titer – ELISA 
 
The amount of p24 HIV-1 viral capsid protein was detected using the HIV-1 p24 ELISA 
Kit (XpressBio, USA) according to manufacturer´s instructions. Physical titer was 
calculated based on the assumption that approximately 2000 molecules of p24 in one 
physical particle of lentivirus (LP). Therefore, one LP contains 8 x 10-5 pg of p24 (2000 
x molecular weight/Avogadro) or 1 ng of p24 equals 1.25 x 107 LPs. A well packaged 
lentivirus vector will have 1 TU for every 100 -1000 LPs. A supernatants titer of 106 








2.3. RNA biochemistry 
 
All procedures involving RNA were carried out under RNAse free conditions. 
RnaseZap RNAse decontamination solution (Thermo Fisher Scientific, USA) was used 
to decontaminate any materials that were not previously RNAse free.  
 
2.3.1. Northern blots 
 
Total RNA and nuclear and cytoplasmic RNA fractions were separated on Novex 10% 
or 15% TBE-urea gel (Thermo Fischer Scientific, United States), and transferred to a 
BrightStar Plus Positively Charged Nylon Membrane (Thermo Fischer Scientific, 
USA).The membrane was cross-linked chemically with N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride and 1-Methylimidazole (Sigma-Aldrich Merk, 
Germany)  and hybridized with a 5′ end biotinylated oligonucleotide probes  that has a 
complementary sequence to each target (Sigma-Aldrich, Germany). 
Chemiluminescence signals were analysed using the Chemiluminescent Nucleic Acid 
Detection Module Kit (Thermo Fischer Scientific, United States) on an ECL Chemocam 
Imager (INTAS, Germany). Probe sequences can be found in table 7. 
 





















2.4.1. Buffers and media 
 
Buffers used for DNA extraction and Northern blot and bacterial media can be found 





Table 8: Buffers and bacterial media composition 
Solution Composition 
Lactate broth (LB) medium Yeast extract (5 g/L)  
 Trypton (10 g/L)  
 NaCl (5 g/L) 
  
LB-Agar Yeast extract (5 g/L)  
 Trypton (10 g/L)  
 NaCl (5 g/L) 
 Agar (7.5 g/L) 
  
SOC medium 0.5% Yeast Extract 
 2% Tryptone 
 10 mM NaCl 
 2.5 mM KCl 
 10 mM MgCl2 
 10 mM MgSO4 
 20 mM Glucose 
  
TAE buffer 40 mM Tris-HCl  1 mM EDTA  
 20 mM acetic acid 
 adjust to pH 7,0 
  
TBE running buffer 89mM Tris Base 
 89mM Boric acid 
 2mM EDTA (free acid) 
  Adjust pH to 8.3 
 
 
2.4.2. Chemicals  
 





Table 9: Chemicals and manufacturer information 
Chemicals  Manufacturer  
2-propanol  Merck-Millipore, Germany  
Acetic acid  Carl Roth, Germany  
Agar-Agar  Carl Roth, Germany  
Agarose  Carl Roth, Germany 
Ampicillin  Carl Roth, Germany  
Boric acid  Sigma Aldrich, MO, USA  
Bovine Serum albunin  Fluka, MO, USA  
Calcium chloride (Cellpure)  Carl Roth, Germany  
Chloroform  Merck Millipore, Germany  
d´NTPs  Sigma Aldrich, MO, USA  
di Sodiumhydrogenphosphate  Carl Roth, Germany  
Diethyl pyrocaronate  Sigma Aldrich, MO, USA  
Dimethylsulfoxid  Roth, Germany  
DMSO  Carl Roth, Germany  
EDTA  Applichem, MO, USA  
Ethanol  Merck-Millipore, Germany  
Ethidiumbromide  Carl Roth, Germany  
Fetal calf serum  Gibco, MA, USA  
Geneticin  Gibco, CA, USA  
Glucose  Carl Roth, Germany  
HEPES  Carl Roth, Germany  
HPLC-Wasser  Sartorius, Germany  
Kanamycin  Applichem, MO, USA  
Loading Dye (DNA)  Thermo Fischer, MA, USA  
Magnesium chloride Carl Roth, Germany 
Magnesium sulfate Carl Roth, Germany 
PBS-Dulbecco  PAA, MA, USA  
Penicillin/streptomycin  PAA, MA, USA  
Poly(ethyleneimine) PEI 
solution  
Sigma Aldrich, MO, USa  
Polyethylenglycol 8000  Sigma Aldrich, MO, USA  
Potassium hydroxyide  Carl Roth, Germany  
Potassium chloride  Carl Roth, Germany  
Puromycin Dihydrochloride  Gibco, MA, USA  
RNase  Sigma Aldrich, MO, USA  
Sodium butyrate  Sigma Aldrich, MO, USA  
Sodium chloride  Carl Roth, Germany  
Sodium hydroxid  Carl Roth, Germany  
Sodiumsulfate  Merck, Germany  
T4 DNA Ligase  Promega, WI, USA  
Tris acetate  Carl Roth, Germany  
TRIS base  Sigma Aldrich, MO, USA  
Tris-HCl  Sigma Aldrich, MO, USA  
Trypanblue  PAA, MA, USA  
Trypsin-EDTA  PAN, MA, USA  
Trypton / Pepton  Carl Roth, Germany  








Table 10: Machines, models and manufacturer information 
Equipments  Model  Manufacturer 
Balance  EG 620-3NM  Kern & Sohn GmbH, Germany  
Chemiluminescence System  ChemoCam Imager  INTAS, Germany  
Centrifuge  Heraeus Megafuge 8R  Thermo Fisher Scientific, MA, 
USA  
Centrifuge  Heraeus Fresco21  Thermo Fisher Scientific, MA, 
USA  
E-Gel system  E-Gel iBase System  Life Technologies, CA, USA  
Freezer (-20°C)                                Bosch, Germany  
Freezer (-80°C)  MDF-DU500VH-PE  Panasonic, Japan  
Freezer (-150°C)  ULT7150-9-D  Thermo Fisher Scientific, MA, 
USA  
Flow Cytometer  LSR II Flow Cytometer  BD Bioscience, NJ, USA  
Gel documentation system  Gel iX Imager  INTAS, Germany  
Ice machine  ZBE 70-35  Ziegra, Germany  
Incubator  Heracell VIOS 160i  Thermo Fisher Scientific, MA, 
USA  
Incubator  IN75  Memmert, Germany  
Incubator  Ecotron  Infors HT, Switzerland  
Microscope  Axio Vert. A1  Zeiss, Germany  
PCR Thermocycler  Labcycler  Sensoquest, Germany  
PCR Thermocycler  2720 Thermal cycler  Applied Biosystems, MA, USA  
pH meter  SevenCompactTM S210  Mettler Toledo, OH, USA  
Plate Reader  Synergy 2  BioTek, VT, USA  
Platform Rocker  PMR-30  Grant bio, Cambridge, UK  
Power supply  EV231  Consort bvba, Belgium  
Real-Time PCR System  StepOneTMPlus Real-Time Applied Biosystems, USA 
Safety Cabinet  Safe 2020  Thermo Fisher Scientific, MA, 
USA  
Thermoblock  ThermoStat plus  Eppendorf, Germany  
Thermoblock  CTM  HTA-BioTec, Germany  
Tissue slicer 51425 Stoelting, Ireland 
Vortexer  Vortex-GenieTM 2  Scientific Industries, NY, USA  
Water bath  WNB10  Memmert, Germany  
   
   
   
2.4.4. Software 
 
Software used to produce schematic drawings and data analysis: 
ChemDraw Professional 15.1 (University of Göttingen licence) 
Flowing software 2 
GraphPad Prism 6 (DPZ licence) 
Microsoft Excel 365 
Microsoft Word 365 




Serial Cloner 2.6 
StepOnePlus Systems software 
3. Results 
 
3.1.  Transgene delivery tools 
 
The delivery of transgenic information into cells, tissues or animals is a basic 
requirement for genetic manipulations that in turn enables phenotypic changes in 
research questions, disease modelling and the development of therapies. Here, I 
focused on the utilization of viral vectors to carry transgenes into cells and tissues and 
biotechnological improvements of the tropism of lentiviral vectors and, with less priority, 
the efficiency of Adeno-associated vectors (AAV). 
3.1.1. LV production, titer determination and concentration 
 
Lentiviruses were produced as described in materials and methods (2.2.5). Usually, 
LV bud from the producer cell´s plasma membrane, carrying a patch of its lipid bilayer 
and the proteins located there are subsequently released to the cell culture 
supernatant (SN). The SN, i.e. conditioned medium containing LV particles is 
harvested, cleared and can afterwards directly be used for transduction of target cells 
or titer-determination (figure 8). The concentration of the viral SN is an optional step 
that enables adjustments of the quantity of virus to be used, thus enabling improvement 
of the overall performance through the option of increased multiplicities of infection 
(MOI, number of recombinant LVs per target cell). There are several methods and 
techniques available for the LV-concentration. The biophysical method of PEG (poly-
ethylene-glycol) precipitation is a straight-forward an easy method, but it leads to a 
higher amount of impurities in the concentrated virus pellet and shorter storage time. 
Ultracentrifugation in sucrose cushions is also very affordable and direct, but the 
disadvantages include i) the extensive manipulation of the viral SN, which can lead to 
contaminations and ii) the necessary use of a specialized equipment, i.e. an 
ultracentrifuge with appropriate containers for S2 material manipulation. For the 
purposes of this study, the concentration method of choice was commercially available 
centrifugation tubes with appropriate molecular weight exclusion filters (e.g. Vivaspin 
– Sartorius). It is a more cost-intensive, but easy and reliable method leading to a pure 







Figure 8. Second generation lentivirus production workflow. LV are produced by 
transfection of a producer cell line (HEK293FT) with three separate plasmids 
containing 1) Envelope glycoprotein (pCMV-VSV-G / pHCMV-Rabies-G), fusogenic 
molecule (pTargeT-fuHA)  and/or targeting molecule (pDisplay-scFv-TrkB / pDisplay-
svFv-Her2/neu); 2) HIV-1 structural components gag, pol, rev (psPAX2) and 3) a 
packing plasmid containing a gene of interest flanked by viral LTR regions. The LV 
tropism can be altered by utilizing different envelope plasmids. In this study VSV-G 
and Rabies-G originated from envelope plasmids provided by addgene.org. Constructs 
to alter LV tropism were generated in house for co-expression of single-chain 
antibodies and fusogenic molecule (see next topic). Viral particles are secreted into 
medium supernatant which is harvested for clearance, concentration and titer 
evaluation. Packing plasmids for GFP (pLenti-CMV-GFP-Neo) and RFP (pLemiR-NS) 
expression were obtained from addgene.org. An shRNA construct (pLKO-shRNA-
CRLF3) and a sgRNA construct (lentiGuide-Puro-sgRNA-GFP) were generated in 
house.    
 
The assessment of the number of viral particles produced was done by tittering of the 
viral SN. The amounts of HIV-1 capsid protein p24 was detected by ELISA assay and 
in addition the physical titer was calculated in transducing units per volume (TU/mL). 
For LV carrying GFP as GOI, a functional titer could also be calculated by utilizing a 
serial dilution of viral SN to transduce cells, which were later analysed by flow 
cytometry (FACS). The titer is calculated using the percentage of fluorescent cells, the 




3.1.2. Pseudotyping and re-targeting LV 
 
Recombinant Lentiviral vectors are potent gene delivery tools for both clinical and 
research purposes. Genetic engineering of HIV-1 viruses gave rise to a versatile 
delivery tool that safely targets cells of choice by manipulation of expression of 
glycoproteins on the viral envelope, in a process called pseudotyping. However, there 
is still a lack of targeting specificity that can be reached by conventional manipulation 
of such molecules. Increasing the specificity of viral vectors is desirable to decrease 
the required amounts of viruses while at the same time being used to reduce the 
chances of cell toxicity or activation of an immune response in animal models or human 
patients. Figure 9 shows a schematic view of the pseudotyping and re-targeting 
strategy of LV covered in this thesis. The drawings show models for viral particles and 
the molecules inserted on the viral envelope for altering the tropism.  
 
Figure 9. Models of pseudotyped and re-targeted LV. Pseudotyped viruses carry 
glycoproteins prevenient from other virus species to alter their tropism. In this thesis 
the vesicular stomatitis virus glycoprotein (VSV-G) and Rabies virus glycoprotein 
(Rabies-G) were produced. Re-targeted viruses have their tropism altered by 
expression of other molecules on the viral envelope. Re-targeted viruses co-
expressing the variable fraction of a single-chain antibody (scFv) and a fusogenic 





3.1.3. Pseudotyped LV successfully express transgenes in mammalian target 
cell lines 
 
In this thesis, HIV-1 based LV particles were produced and pseudotyped with, among 
others, vesicular stomatitis virus glycoprotein (VSV-G), generating recombinant 
viruses with a broad range of transduction and high levels of transgene expression 
(73,3% ± 5,4% of fluorescent HEK293 cells). These viruses served as controls for the 
other pseudotyped and retargeted viruses and transduction efficiencies were 
compared (see figure 10). The transgene or gene of interest (GOI) carried by the viral 
particles were either green fluorescent protein (GFP) or red fluorescent protein (RFP). 
This way, the transduction patterns could be analyzed by microscopy and fluorescence 




Figure 10. LV-VSV-G transduction pattern in HEK293 and Hela cells. Cells were 
transduced with 150 MOI (150 viral particles per cell). 72h after transduction cells were 
analysed under epifluorescence microscope for RFP expression and FACS. In 
average around 73,3% ± 5,4% of HEK293 cells were fluorescent and 65,1% ± 3,3% 





Rabies virus is a neurotropic virus that infects peripheral neuronal cells and is 
transported retrogradely to the central nervous system (Gluska et al., 2014). The 
tropism, binding and fusion of these viruses is mediated by their glycoprotein (Rabies-
G) which targets nicotinic acetylcholine receptors (nAchR) (Lafon, 2005). In order to 
produce LV with narrowed tropism towards nervous tissue, HIV-1 based LV were 
pseudotyped with Rabies-G and their transduction patterns were investigated in figure 
11. Human neuroblastoma derived differentiated cells (SH-SY5Y, see figure 18) were 
utilized as a nervous tissue like model. Although the transduction efficiency of these 
viruses was lower than the LV-VSV-G (27,6% ± 4,7% of fluorescent HEK293 cells 
against 73,3% ± 5,4%), the viral particles were able to transduce cell lines from origins 
other than nervous tissue such as cervical cancer derived Hela and human embryonic 
kidney HEK293. A summary of transduction efficiencies measured as percentage of 
fluorescent cells can be found in table 11. 
 
Figure 11. LV-Rabies-G transduction pattern in HEK293, Hela and differentiated 
SH-SY5Y cells. Cells were transduced with 150 MOI (150 viral particles per cell). 72h 
after transduction cells were analysed under epifluorescence microscope for RFP/GFP 
expression and by FACS. In average around 27,6% ± 4,7% HEK293 cells, 17,3% ± 
3,0% Hela cells and 11,1% ± 3,1% SH-SY5Y+RA cells were fluorescent. Scale bar: upper 







Table 11: Transduction efficiency of pseudotyped LV 
Cell line Lentiviruses used for transduction 
  LV-VSV-G LV-Rabies-G 
HEK293 73,3% ± 5,4%  27,6% ± 4,7%  
Hela 65,1% ± 3,3% 17,3% ± 3,0% 
SH-SY5Y+RA 55,2% ± 2,1% 11,1% ± 3,1% 
 
3.1.4. Pseudotyped LV leads to successful transgene expression in rat brain 
dissociated culture 
 
Lentiviruses are especially suited for use in neurosciences for they can infect non-
dividing cells like neuronal cells. Thereby LV-VSV-G and LV-Rabies-G were tested on 
rat brain dissociates cultures and their transduction pattern was analyzed by 
microscopy. LV-VSV-G led to an average of 52.2% of transduced cells (manual 
counting), while LV-Rabies-G transduced around 9,6% of the cells in culture (figure 
12). Virus were added after 13 DIV and cultures could be kept for at least 14 days after 
















Figure 12. LV-VSV-G and LV-Rabies-G transduction pattern in Wistar rat brain 
dissociated culture. Virus were added after 13 DIV. 72h after transduction cells were 
analysed under epifluorescence microscope for RFP expression. LV-VSV-G treated 
cultures expressed the transgene in around 52.2% of the cells, while LV-Rabies-G 
treated cells were 9.6% fluorescent. No signs of cytotoxicity were observed on treated 
cells when compared to non-treated controls for at least 14 days after transduction. 
Scale bar: 20µM. 
 
3.1.5. Pseudotyped LV leads to successful transgene expression in ex vivo 
non-human primates organotypic brain slices 
 
Advancing an extra step regarding the complexity of experimental models, cortical 
brain slices from a non-human primate species (Macaca fascicularis) were prepared 
and kept alive in culture dishes as an ex vivo experimental model. Lentiviruses were 
added directly on top of the cultured slices and successful delivery of RFP was 
qualitatively assessed after 13 days in vitro (DIV) as shown in figure 13. The slices 
were kept for at least 20 DIV with no signs of increased degradation on treated slices 
when compared to non-treated slices. The identity of the cells was not checked but 
morphology indicates glial cells to be the most successful transduced given the size 







Figure 13. LV-VSV-G and LV-Rabies-G transduction pattern in Macaca 
fascicularis organotypic brain slices. Brain slices were kept on a permeable 
membrane in such a way that the slice had access to the culture medium and 
atmospheric gases. Slices were transduced on 10 DIV. 72h after transduction cells 
were analysed under epifluorescence microscope for RFP expression. Given the 
nature of the material the quantification of percentage of fluorescent cells is difficult but 
qualitative assessment show a higher efficiency of LV-VSV-G. No differences in tissue 
degradation were observed on treated slices compared to the controls for at least 7 
days after transduction. Scale bar: 100µM. 
 
 
3.1.6. Re-targeted LV: narrowing viral tropism by expression of single chain 
antibodies and fusogenic molecule 
 
Yang and colleagues (Yang et al., 2006), (Lei et al., 2009), (Lei et al., 2010) have 
worked on a different approach towards modifying the molecules on LV envelope in 
order to increase specificity of transduction. They used the variable fraction of a single 
chain antibody (scFv) for their high binding specificity. Furthermore, the reduced size 
of these molecules allowed for the fusion with a transmembrane protein for anchorage 
on the viral envelope. However, this chimeric protein alone is not able to drive fusion 
of the viral envelope with the host cell membrane, a fundamental step on the delivery 




defective viral glycoprotein mutated to preserve its fusogenic property. In this study the 
same rational was followed. Two re-targeted LV were produced targeting different 
molecules. In both viruses the fusogenic molecule was a modified hemagglutinin (HA) 
from the influenza virus. As shown in figure 14, three point mutations were inserted on 
the binding segment of the molecule in order to refrain it from its biding activity. This 
mutated or fusogenic HA (fuHA) was then co-expressed with two different svFv: 
1st) scFv-TrkB: the tyrosine kinase receptor (TrkB) is a receptor for brain-derived 
neurotrophic factor (BDNF) and it is known to be highly expressed in nervous tissue 
(Huang and Reichardt, 2003). By producing LV bearing a specific scFv for TrkB, the 
working hypothesis was that the tropism of LV would be narrowed towards nervous 
tissue exposing TrkB. For research and clinical applications, a neurotropic LV is 
valuable because it can deliver transgenes in a safer manner in such a delicate system 
as the central nervous system. 
2nd) scFv-Her2/neu: human epidermal growth factor receptor 2, also known as 
Her2/neu is an oncogene (Coussens et al., 1985) known to be overexpressed in a 
variety of breast cancers, nowadays being used as a marker of the progression of the 
disease and potential therapeutic target (Mitri et al., 2012). The advent of genetic 
manipulation tools such as silencing RNA (siRNA) and genome editing tools such as 
the CRISPR-Cas9 system brought new light onto potential new therapies for cancer 
by allowing the inhibition of the expression of proto-oncogenes and activating the 
expression of tumor suppressor genes.Therefore, delivery tools that are highly specific 







Figure 14. Schematic view of proposed mode of action of fusogenic molecule. 
Re-targeted LV co-expressing a targeting molecule (single-chain antibody – scFv in 
green) and a fusogenic molecule to drive fusion (fusogenic hemagglutinin – fuHA in 
red) on the envelope recognizes a target molecule on the cell membrane (upper panel, 
left). After binding and endocytosis, the fusogenic molecule will promote fusion of the 
viral envelope and release of viral capsid upon acidification of endosome. Lower panel: 
Fusogenic molecule was generated by insertion of three point-mutations (Y106F, 
E199Q, G237K) on the binding domain of hemagglutinin from influenza virus, which 
prevents it from binding with host cell. The fusion activity is not disrupted. HA1: binding 





For the expression of scFv´s on the cell membrane and later incorporation into viral 
envelope, this molecule was fused with a Platelet-derived growth factor receptor 
transmembrane domain (PDGFR-TM) construct contained in a plasmid commercially 
available (pDisplay – Invitrogen, USA). This construct is specific for guiding expression 
of proteins on outer cell membranes and contains among others a myc tag for protein 
detection (figure 15). svFv-TrkB and svFv-Her2/neu were cloned into the vector 
creating a chimeric PDGFR-svFv protein for expression on the cell membrane. In order 
to determine whether the scFv construct was indeed being expressed on the outer 
membrane surface an immunoassay was developed:  
 
Figure 15. Construct for expression of molecules on mammalian cell 
membranes. The commercially available pDisplay system for display of proteins on 
the outer cell membrane contains a Platelet-derived growth factor receptor 
transmembrane domain (PDGFR-TM) for anchoring proteins to the membrane, HA tag 
and myc tag for protein detection. scFv targeting Her2/neu and TrkB were cloned into 
in the multiple cloning site according to manufacturer’s instructions creating chimeric 
PDGFR-scFv proteins.  Source: pDisplay vector Catalog no. V660-20 Invitrogen. 





HEK293 cells were transfected with pDisplay empty, pDisplay-scFv-TrkB and 
pDisplay-scFv-Her2/neu. 72h later cells were fixed with paraformaldehyde, unspecific 
epitopes were blocked with BSA and then incubated with primary anti-myc tag 
antibody. An appropriate secondary antibody conjugated with Alexafluor 488 was used 
and fluorescence was analysed by FACS. Figure 16 shows that there is a striking 
increase in average fluorescence on the transfected cells in comparison to wt cells. 
The constructs containing scFv also showed a slightly higher average fluorescence. 
Figure 16. Histogram of immunoassay for detection of protein on the outer cell 
membrane in HEK293 cells. Cells expressing pDisplay constructs and wt cells were 
treated for staining of myc tagged proteins with Alexa 488 conjugated antibody. Only 
proteins expressed on the outer cell membrane could be detected because the cells 
were not permeabilized. Average fluorescence intensity was measured by FACS. 
Histograms show a much higher average fluorescence intensity on cells expressing 
pDisplay in comparison with the wt (black line). Cells expressing pDisplay fused with a 


















3.1.7.  LV-scFv-TrkB: targeting nervous tissue 
 
Lentiviruses bearing a scFv-TrkB and a fuHA were tested in different cells lines. A LV-
fuHA carrying only the fusogenic molecule was used as a negative control, once it is 
not expected to drive fusion of virus and host cell. To check whether our cell lines 
expressed the TrkB receptor, a PCR and qPCR using β2M as housekeeping gene 
were performed and the electrophoresis gel as well as the relative expression of TrkB 
are shown in figure 17. The higher amounts of the receptor were detected in 
differentiated SH-SY5Y. These cells, upon incubation with retinoic acid (RA) 
differentiate into mature neuronal-like cells including their morphology  (Påhlman et al., 
1995), (Agholme et al., 2010) (see figure 18). Therefore, the re-targeted viruses were 
tested on these cells first, as shown in figure 19. Although with low efficiency, LV-scFv-
TrkB were able to drive expression of the GOI.  
 
Figure 17. TrkB expression detection by PCR and qPCR. Expression of TrkB 
receptor in various cell lines were detected by PCR (left panel and quantified by qPCR 
(right panel). Observe the steep increase in TrkB expression upon differentiation in 
SH-SY5Y cells (355-fold increase when compared to HEK296 wt). Hela cells show 
neglectable expression and therefore could be used as a negative control when 
targeting TrkB. β2M was used as housekeeping gene. Error bars represent SEM.  
 
To access the specificity of these viruses, other cell lines showing low expression of 
TrkB were also transduced, including Hela and HEK293. Surprisingly, these cells also 






Figure 18. Neuroblastoma derived SH-SY5Y cells morphology upon 
differentiation. SH-SY5Y cells can be differentiated into mature neuron-like cells by 
incubation with retinoic acid (RA). 10µM RA for 72h leads to cells with longer, thinner 
and more abundant processes. Differentiated cells express neuronal markers such as 
NeuN.      
 
 
Figure 19. LV-fuHA and LV-scFv-TrkB-fuHA transduction pattern in differentiated 
SH-SY5Y.  As expected fuHA alone do not lead to transgene expression. LV-scFv-
TrkB-fuHA leads to low efficiency expression. 72h after transduction cells were 
analised under epifluorescence microscope for RFP intensity. Scale bar: upper image: 






Figure 20. LV-scFv-TrkB-fuHA transduction pattern in HEK293 and Hela.  Though 
these cell lines show low expression of TrkB receptor (see figure 17), LV-ScFv-TrkB-
fuHA lead to expression of RFP in a few cells. 72h after transduction cells were 
analised under epifluorescence microscope for RFP intensity. Scale bar: 20µM. 
 
3.1.8. LV-scFv-Her2/neu: targeting breast cancer cells 
 
As described before, LV carrying scFv-Her2/neu and fuHA were produced. The 
expression levels or Her2/neu in target cell lines were detected by qPCR as shown in 
figure 21. A high Her2/neu expression cell line SKBR3 (breast cancer) as well as low 
expression HEK293 were transduced. Figure 22 show the transduction patterns on 
these cell lines. Interestingly, all cell lines tested expressed the transgene and 








Figure 21. Her2/neu expression detection by qPCR in several cell lines. Higher 
amounts of Her2/neu are expressed in MCF7, SKBR3 and SW480, all cancer cell lines. 
β2M was used as housekeeping gene. Error bars represent SEM.  
 
 
Figure 22. LV-Her2/neu-fuHA transduction pattern in SKBR3 and HEK293. LV-
ScFv-Her2/neu-fuHA lead to expression of GFP with low efficiency. Surprisingly LV-
fuHA also leads to expression of transgene. 72h after transduction cells were analysed 







3.2. Improving the efficiency of viral vectors 
 
Besides specificity, efficiency is also a quality desired when it comes to gene delivery 
tools. The higher the efficiency, the lower amounts of viruses can be used leading to 
less potential risks to the target organism or cell. 
3.2.1. The tetraspanin CD9 and LV 
 
A study in which I am a contributing author (Böker et al., 2018) showed that the co-
expression of a membrane protein with VSV-G on the viral envelope resulted in LV that 
were more efficient in delivering the transgene as assessed by FACS. The tetraspanin 
CD9 is a membrane protein that is known to be involved in several cell processes such 
as adhesion, proliferation (Hemler, 2005) and in facilitating fusion of the sperm and 
egg during fecundation (Miyado et al., 2000). The LV-VSV-G-CD9 viruses promoted a 
faster and higher expression of the GOI when compared to LV-VSV-G (figure 23). The 





Figure 23. CD9 improves LV efficiency. The CD9 tetraspanin was co-expressed with 
VSV-G on the viral envelope generating LV-VSV-G-CD9.The transduction patterns 
and viral titer were compared to the control LV-VSV-G. Co-expression of CD9 did not 
influence on viral titer as assessed by physical titer (ELISA) and genomic titer (upper 
panel). LV-VSV-G-CD9 lead to faster and improved expression of RFP as assessed 
by microscopy in HEK293 cells at different time points (lower left panel). Percentage 
of fluorescent cells using different MOI by FACS analysis show higher efficiency of LV-
VSV-G-CD9 (lower right panel). Error bars show SD. Scale bar 200µM. Source: (Böker 









3.2.2. The tetraspanin CD9 and LV-Rabies-G 
 
To test whether co-expression of the CD9 tetraspanin and Rabies-G would have a 
positive influence on LV efficiency, LV-Rabies-G-CD9 was produced and its 
transduction patterns were compared to those of LV-Rabies-G. Same MOI of both LV 
were added to four different cell lines including HEK293, SH-SY5Y and hard-to-
transfect suspension cell lines Jurkat (T-cell line) and Raji (B-cell line). The physical 
titers were calculated by ELISA (figure 24). Transduction patterns were analysed by 
microscopy and FACS (figure 25). There was no significant difference on viral amounts 
produced when CD9 was co-expressed. The viral efficiency did not change 
significantly among the cell lines tested.  
 
Figure 24. Physical titer comparison LV-Rabies-G vs LV-Rabies-G-CD9. Physical 
titer of LV-Rabies-G and LV-Rabies-G-CD9 was measured by HIV-1 p24 protein 
quantification in ELISA and calculated as transducive units per mL (TU/mL). There was 
no significant difference on the number of viral particles produced in CD9 expressing 








Figure 25. Transduction pattern and fluorescence quantification of LV-Rabies-G 
and LV-Rabies-G-CD9 treated cells. HEK293, SH-SY5Y, Jurkat and Raji cells were 
transduced with 150 MOI LV-Rabies-G and LV-Rabies-G-CD9 and percentage of 
fluorescent cells were quantified by FACS (upper panel). Although both viruses were 
functional, there was no significant difference in the number of transduced cells when 
CD9 was present. Lower panel shows transduction patter on HEK293 and SH-SY5Y. 















3.2.3. The tetraspanin CD9 and exosome associated Adeno-associated virus 
  
Although AAV are non-enveloped viruses, studies showed that the association of these 
viruses with extracellular vesicles of endosomal origin, called exosomes had beneficial 
effects on AAV transduction efficiency (Maguire et al., 2012). Exosomes are small 
extracellular vesicles (30-100nM) secreted by virtually all mammalian cells. When 
associated to AAV (exo-AAV) it was hypothesized that these particles could transduce 
target cells more efficiently and the natural tropism of AAV could be altered by 
manipulation of molecules expressed on exosomes membrane.  
On the course of Lara Schiller´s project we sought to further proof whether exosomes 
had in fact a positive effect on AAV transduction efficiency and extend the concept of 
beneficial impact of CD9 on viral efficiency by studying CD9-enriched exo-AAVs 
transduction patterns. A summary of the findings is shown in figure 26. In brief, CD9 
overexpression on AAV producer cells increases the number of exosomes secreted, 
which lead to a higher amount of exosome associated AAV. The CD9 exo-AAVs were 







Figure 26. CD9 boosts exosome production and exo-AAV efficiency. AAvs were 
produced in wt and CD9 overexpressing producer cell lines. Total amount of exosomes 
was quantified in conditioned media from wt and CD9 cells. Upper left panel shows an 
increased production of exosomes by high CD9 cells. **p˂0.01. Error bars show SD. 
Pellets obtained after centrifugation of conditioned media at 100.000xg were 
resuspended and separated in iodixanol density gradient. 18 fractions were prepared 
(center panel).  AAV and exosome content were analysed in the fractions by qPCR 
and acetylcholinesterase activity assay respectively. High CD9 cells produced 
increased amounts of exo-AAV as shows by higher expression of AAV genomic copies 
in exosome enriched fractions 4-13 (right panel). Comparison of genomic titer and 
functional titer show that CD9 exo-AAV were in average 26% more efficient in 
transducing cells when compared to wt exo-AAV. The higher slope of the red line 
indicates that the same amount of exo-AAV (as calculated by genomic titer) leads to 
higher number of transduced cells (higher calculated TU) when CD9 is present. 




3.3. Genetic manipulation by utilization of modified viral vectors 
 
Modified viral vectors that have different tropisms and are more efficient when 
compared to classical viral particles were successfully produced and characterized in 
different in vitro and ex vivo models as shown above. The next sections will refer to 
practical applications of the generated viral tools in order to deliver genetic 




with CRISPR-Cas9 system, the use of an RNAi system to unfold a possible role of a 
cytokine-receptor like molecule in cell protection and investigation of a hypothesized 
role of the U3 snoRNA as a source of functional miRNA.  
 
3.3.1 Genetic manipulation at genome level: the CRISPR system 
 
The CRISPR-Cas9 system is a genome editing technique that has been en vogue for 
the past decade. Derived from a bacterial archaic immune system, the system has 
been adapted for use in mammalian cells where it can be used for gene expression 
disruption or activation. The broad applications of the system make it an important and 
potentially powerful tool for the treatment of genetic disorders such as cancer and 
neurodegenerative diseases.  
As one of the many applications of the LV tools afore mentioned, LV carrying CRISPR-
Cas9 system components were produced and tested in different cell lines. HEK293 
and SH-SY5Y stabling expressing GFP and Cas9 protein were generated in two steps: 
1st) Transduction with LV-VSV-G-GFP: 150 MOI were added to wt cells. 72h later 
selection of GFP expressing cells was started with geneticin. The optimal amount of 
antibiotic for selection was found to be 1mg/mL for HEK293 and 800µg/mL for SH-
SY5Y.  
2nd) Transduction with LV-VSV-G-lentiCRISPRv2: for expression of Cas9, fabricated 
in the same procedure as above. After 72h cells were selected with 0,5µg/mL 
Puromycin. After three rounds of splitting, cells were ready to be used. 
The HEK293-GFP-Cas9 and SH-SY5Y-GFP-Cas9 cells were then transduced with LV-
VGV-G-sgRNA-GFP. The viruses transduced for the expression of a guide RNA 
specific for GFP. In association with the Cas9 protein, the Cas9-sgRNA complex 
should lead to a double strand break (DSB) in the GFP gene and overall lower GFP 
expression. As analysed by FACS, figure 27 show reduction in the average 
fluorescence intensity in both cell lines tested, which can be observed by the shift a 
population of GFP expressing cells towards the lower GFP intensities area in the chart 






Figure 27. GFP expression disruption by CRISPR-Cas9 in HEK293 and SH-SY5Y. 
Cells stabling expressing GFP and Cas9 were treated with LV carrying a guide RNA 
for GFP. Observe the decreased average fluorescence intensity on cells expressing 
Cas9. Additionally, HEK 293 cells stabling expressing an endonuclease deficient Cas9 
(dCas9) show no significant decrease in fluorescence intensity, indicating that no 
effective DSB occurred. 
 
A HEK293-GFP-dCas9 cell line was also generated as mentioned before as a control. 
These cells express an endonuclease deficient Cas9 (dCas9) that is utilized in CRISPR 
interference and CRISPR activation systems (see section 1.3.3.1-2). This molecule 
can bind to the DNA strand through association with sgRNA but do not lead to DSB. 
The purple line on the histogram in figure 27 show that the average GFP expression 
levels on the dCas9 expressing cells is like those of the HEK293-GFP, indicating that 
the system works together with the LV tool.   
3.3.2 Genetic manipulation at the mRNA level: gene silencing through RNA 
interference 
 
Genetic manipulation can be achieved through targeting different steps of gene 
expression. As described above the CRISPR-Cas9 system targets the very first step 
of gene expression by targeting the genome itself, altering the transcription of DNA to 
RNA. One can also disrupt gene expression by targeting a later step of the process. 
Short hairpin RNA (shRNA) target mRNA molecules specifically through 
complementarity to its target sequence (Paddison, 2002). Target mRNA activity is then 
repressed by association with RNA-induced silencing complex (RISC) in a process 
called RNA interference (RNAi).  
This system can also be coupled with the LV tools for delivery of shRNA constructs. In 




These experiments were carried out in collaboration with Nina Hahn and the group of 
the Dept. of Cellular Neurobiology from the Schwann-Schleiden Research Center lead 
by Dr. Ralf Heinrich in Göttingen. One of the scientific questions is whether a cytokine 
receptor-like factor (CRLF3) can lead to neuroprotection by interaction with 
erythropoietin (Epo). Similar effects have been documented by his group in 
invertebrates (Hahn et al., 2017) and the next step is to assess whether the same 
process is conserved in mammalians.  
Manipulation of expression of the molecule of interest (CRLF3) becomes important 
when one intends to evaluate its role in cell physiology. Overexpression and gene 
expression experiments were performed:  
1) Overexpression of CRLF3: HEK293 cells were transfected with the construct 
containing the human orthologue of CRLF3 pHCMV-CRLF3 
2) Gene repression: Addgene.org offers a suite of constructs and protocols for 
production of LV containing shRNA constructs (pLKO.1 TRC-Cloning Vector). 
Therefore LV-VSV-G-shRNA-CRLF3 was produced based on this protocol in 
order to disrupt CRLF3 expression.  
The resulting alteration in CRLF3 expression was investigated by qPCR in figure 28. 
Overexpression lead to a 94-fold increase in CRLF3 expression when compared to wt 










Figure 28. Relative expression of CRLF3 in HEK293 cells as assessed by qPCR. 
On the left panel observe an 80% reduction in CRLF3 expression upon treatment with 
LV-VSV-G-shRNA-CRLF3. On the right panel cells were transfected with a construct 
containing a cassette expression for CRLF3 under the control of CMV promoter. There 
was a 94-fold increase in CRLF3 expression. 
 
Since the main question is the role of the molecule in neuroprotection, neuroblastoma 
cells were exposed to harmful stimuli and as a first step the CRLF3 expression levels 
were checked. SH-SY5Y and differentiated cells were exposed to 24h hypoxic 
conditions with O2 tension below 1%. Figure 29 shows that expression levels of CRLF3 
increase in differentiated cells by 62%, while wt type cells exposed to hypoxia showed 
62% decreased expression. Differentiated cells exposed to hypoxia have an even 






Figure 29. Relative expression of CRLF3 in SH-SY5Y and differentiated SH-SY5Y 
under hypoxia as assessed by qPCR. Cells were incubated in controlled atmosphere 
containing less than 1% O2 for 24h. Differentiation leads to increase in CRLF3 
expression by 62%. Wildtype cells under hypoxia decreased CRLF3 expression by 
62%. Differentiated cells under hypoxia had an even more accentuated decrease of 
82%.   
 
Besides HEK293 and neuroblastoma, the basal CRLF3 expression levels were also 
quantified in different mammalian cell lines such as Hela, SKBR3 and MCF7 (also a 
breast cancer line). See figure 30. CRLF3 levels were significantly lower in cancer cell 
lines such as cervical cancer Hela and breast cancer SKBR3 and MCF7 when 
compared to HEK293 and SH-SY5Y, an interesting finding considering the postulated 













Figure 30. Expression of CRLF3 in different cell lines measured by qPCR. 
Relative quantification of CRLF3 expression in mammalian cell lines was quantified by 
qPCR. Expression of CRLF3 in cancer cell lines such as Hela, SKBR3 and MCF7 is 
significantly lower when compared to HEK293 or SH-SY5Y. CRLF3 deregulation may 
be related to the general disrupted state of cancer cells. GAPDH expression level was 
used as a control.  
 
3.3.3. Genetic manipulation at the post-transcriptional level: snoRNA U3 as a 
source of microRNA 
 
In order to check whether the 5´domain of U3 is a source of miRNA probes 
complementary to U3 5´domain were utilized in qPCR optimized for detection of 
miRNA (miRcury kit – QIAGEN). HCT116 cells (colorectal carcinoma) lacking 
components of miRNA processing pathways (Dicer, Drosha, XPO5) (Kim et al., 2016) 
had their miRNA-U3 contents analysed and miRNA 34-a (a low functional miRNA) and 
U6 (a small nuclear RNA that participates in the processing of pre-mRNA in the 
nucleus) were used as controls. Figure 31 shows the relative quantification of three 
independent measurements. When Drosha is absent (nuclear processing) the yield of 
U3 derived miRNA is significantly higher, indicating that its processing is Drosha 
independent. On the other hand, when Dicer is absent (cytoplasmic processing) there 







Figure 31. Expression of miR-U3 measured by qPCR. Relative expression 
quantification was achieved by qPCR using probes complementary to the U3 
5´domain. The qPCR amplification products were then electrophoretically separated in 
an agarose gel and the bands were observed.  There is a significant increase in miR-
U3 expression when Drosha is absent. Furthermore, there is no detectable expression 
of miR-U3 when DICER is absent. These results indicate that U3 is processed 
independent of Drosha and is processed in the cytoplasm by Dicer. U6 expression was 
used for normalization. Error bars indicate SEM. Statistical analysis by 2way ANOVA. 
p = 0.0021.  
 
To access the cellular localization of the mature U3, cells were fractionated, RNA was 
isolated to obtain nuclear and cytoplasmic fractions and the RNA was electrophoretic 
separated and blotted for posterior hybridization with probes for U3, U6 as a nuclear 
marker and Val-tRNA as a cytoplasmic marker. In figure 32 the northern blot show 
presence of U3 in the cytoplasm and slightly higher amounts when Dicer is absent. 









Figure 32. Northern blot of nuclear and cytoplasmic expression of U3. Cells were 
fractionated and RNA collected from nuclear and cytoplasmic fractions. RNA was 
separated on a gel and transferred to a membrane for posterior hybridization with 
probes for detection of U3, U6 and Val-tRNA. U6 is known to remain in the nucleus. 
The presence of it on the cytoplasmic fraction indicate possible leaking on the 
fractionation process. Val-tRNA as a cytoplasmic marker. Observe the slightly higher 
amounts of U3 on the cytoplasmic fraction of Dicer KO cells. 
 
The ratio of expression on the cytoplasm over nuclear expression (c/n) was calculated 
and indicates that in the absence of Dicer there is an increased amount of U3 in the 
cytoplasm, corroborating the previous findings and the theory that U3 indeed migrate 
to the cytoplasm and is further processed by Dicer (Figure 33).   
 
Figure 33. Expression of U3 in nuclear and cytoplasmic fractions measured by 
qPCR. Expression of U3 was measured in RNA nuclear and cytoplasmic fractions. The 
ratio cytoplasm/nucleo relative quantification was calculated. A significant increase in 
c/n on Dicer KO cells corroborate the findings in the northern blots and indicates that 
U3 is present in higher amounts in the cytoplasm in the absence of Dicer. Error bars 









4.1. Lentiviruses as gene delivery tools  
 
Lentiviruses are a potent and versatile delivery tool for transgene expression. They 
have a higher packing capacity when compared to other viral vectors such as adeno-
associated viruses (AAV), allowing for delivery of longer genetic sequences. 
Furthermore, LV leads to a stable, long term transgene expression once the delivered 
GOI integrates into the cell host genome. The ability of these vectors to infect non-
dividing cells make them extremely useful tools for use in neurosciences (Naldini et al., 
1996).  
However, like any other delivery systems, LV also present disadvantages, such as the 
fact that the transgene is incorporated into the host genome in a random manner, which 
can lead to interference in normal cell function and increase the risks of oncogeneses 
(Hacein-Bey-Abina et al., 2003), (Ott et al., 2006), (Schwarzwaelder et al., 2007). Non-
integrating LV are an alternative to avoid potential harmful effects of random viral 
genome integration and such system have been used successfully for transient GOI 
expression in muscle (Apolonia et al., 2007), primary stem cells, hematopoietic and 
lymphoid cells (Nightingale et al., 2006). 
LV delivery systems utilized in research are based on HIV backbone, what generate 
concerns regarding immune response for in vivo applications and general safety for 
use in patients and safety measures during the production of the viral particles. 
Nonetheless, several safety precautions have been taken along the years to make sure 
the viral particles produced are safe. The expression cassettes utilized nowadays are 
stripped from any non-essential components from the wildtype HIV (almost 95% of 
original HIV genome is out) (Naldini et al., 1996). The second-generation lentiviral 
production system utilised a vector expressing the three structural HIV-1 genes gag, 
pol and rev. On third-generation systems the rev gene is separated on its own vector 
for the expression of the viral components in separated expression cassettes adds an 
additional layer of safety decreasing the chances of recombination. This system 
requires the transfection of at least four plasmids for LV production, namely the two 




pseudotyping. That can decrease transfection efficiency and viral production. For the 
purposes of this thesis we used a second-generation LV production method. The gag, 
pol and rev genes are encoded by the same plasmid (psPAX2). That allows for a better 
titer since the number of plasmids to be transfected is lower. We chose this system 
because our re-targeting approach already requires an additional plasmid to be 
transfected: targeting and fusogenic molecule. 
The viral particles produced nowadays are also replication deficient, meaning that they 
do not deliver additional viral replication sequences (Zufferey et al., 1998).  
Perhaps the most striking feature of LV is the fact that the tropism of the viral particles 
can be determined by the molecules that are expressed on the producer cell 
membrane. This allows for the manipulation of the tropism of the viruses by exogenous 
expression of targeting molecules of interest by the producer cell lines in a process 
called pseudotyping. In order to broaden the tropism of LV in general the expression 
of a glycoprotein originally expressed by a vesicular stomatitis virus (VSV-G) is used 
to replace the original HIV targeting glycoproteins (Aiken, 1997), (Amado and Chen, 
1999). This molecule confers the produced viral particles the ability to infect a variety 
of mammalian cells increasing the efficiency of transgene expression significantly, with 
low specificity.  
4.2. Advantages of LV in research and gene therapy applications 
 
Researchers have been using and improving the LV system for years now. It is a 
validated tool for effective transgene delivery for several reasons: 
• Easy production: viral particles are secreted into SN, facilitating harvesting and 
purification for in vivo applications; 
• Safety: although unlike AAVs the LV system is based on a pathogenic virus, the 
advent of replication deficient LV and third generation production methods 
makes the system safe enough for use in clinics; 
• The packing capacity of around 8.5kb makes LV the tool of choice for the 
delivery of components of very popular cell biology manipulation tools, such as 
the CRISPR system and opsins for optogenetics; 
• The number of viral particles necessary for efficient use in organisms is 
relatively small when compared to other viral vectors: 108 TU/mL versus 1012 




• Changing the tropism of the viruses is achieved by manipulating expression of 
molecules on viral envelope; 
• Low immunogenicity and lack of previous immunity, (Shaw and Cornetta, 2014);  
• LV are validated tools for use in non-human primates (Dissen et al., 2009). 
These animal models are invaluable (and expensive) tools that require extra 
thought when it comes to genetic manipulation, especially in the field of 
neurosciences. 
Several clinical trials that used LV as delivery tool reported no cytotoxicity in patients 
(Levine et al., 2006), (Thompson et al., 2016), (Palfi et al., 2014), (Palfi et al., 2018).  
4.3. Lentiviral production 
 
4.3.1. Lentiviral safety remarks 
 
HIV-1 based LV are considered level S2 lab safety risk because of the potential 
production of recombinant viruses and potential harmful effects of GOI integration. 
Safety protocols must be followed when manipulating LV, what can be a disadvantage 
of the system:  
1. Not every research institute can operate an S2 facility for viral production, 
storage and manipulation; 
2. The handling and inoculation of LV also requires specialized facilities and 
trained personnel. 
However, when safety protocols are followed properly and second or third generation 
production systems are chosen, LV are a consistent tool for gene delivery.  
4.3.2. Lentiviral titering methods 
 
Regarding the titering methods I used in this study, a few points come to attention: 
• Physical titering by detection of viral proteins through immunoenzymatically 
assays can offer an overestimation of the real viral count. ELISA assays are 
extremely sensitive and there is no way to know for sure whether the protein 
being detected is a part of a full capsid or a defective capsid. The method is 




• Functional titer measured by percentage of fluorescent cells on FACS is a very 
good way of knowing the functionality of produced viruses. Unfortunately, it 
usually offers an underestimation of the actual viral count because a single cell 
can be transduced by a single virus or many viral particles. Another 
disadvantage of the method is the fact that one can only titer LV that contains 
fluorescent proteins as GOI, which limits the application of the method for other 
purposes;  
• Genomic titering is another interesting option and a way of complementing the 
other methods mentioned above. The disadvantage again is an overestimation 
of viral functionality. 
Figure 34 shows the differences of viral amounts obtained in TU/mL when using 
functional titration by FACS and physical titration with ELISA. The chart depicts titering 
of three independent LV production batches. For this study we decided to perform 
functional titering whenever the GOI was a fluorescent protein. For other applications 
such as production of shRNA and sgRNA carrying viruses physical titering was 
necessary.   








Figure 34. Comparison of two titration methods for LV. Functional titer calculated 
by number of fluorescent cells by (FACS) tend to underestimate viral count while 
physical titer (ELISA) tend to overestimate it. Each dot represents a different batch of 
LV production. Each batch was titered by FACS and ELISA, viral amounts were 
calculated as transducive units per mL (TU/mL) and the values were plotted. 
 
4.3.3. Lentiviral concentration methods 
 
The concentration techniques I used in this study also pose advantages and 
disadvantages as mentioned before (see section 3.1.1). The most straightforward 
concentration method I came across in the literature is the polyethylene glycol (PEG) 
precipitation. The fact that one only need to incubate their viral samples overnight and 
pellet the precipitate on an average benchtop centrifuge is a big advantage over 
ultracentrifugation (too laborious and demands specific equipment) and molecular 
weight exclusion filtration (much more expensive). The disadvantage is the fact that 
PEG precipitate absolutely any vesicle on the SN, making the final viral suspension 
“impure” and not suitable for in vivo application, for example. I also found long-term 
storage to be poor since batches of viruses concentrated with this method were not 
functional after a few months, even when stored under standard conditions at -80°C.  
Ultracentrifugation in sucrose cushion proved to be challenging for the extensive 




viral samples occurred much more often in viral batches concentrated in this way. For 
most of the experiments in this thesis, I concentrated viral SN with the use of centricons 
containing molecular weight filters (see section 2.2.6). The viral preparations remained 
stable for at least 18 months at -80°C.  
4.4.  Pseudotyped and re-targeted LV efficiency 
 
As described in sections 3.1.6-8, re-targeted viruses carrying a fusogenic molecule 
(fuHA) and an scFv (scFv-TrkB / scFv-Her2/neu) lead to low efficiency transgene 
expression. A few possible reasons for that are: 
• During LV production all necessary plasmids are transfected at the same time 
on producer HEK293FT cells. It is logical to assume that some constructs will 
be expressed sooner than others. Perhaps the trafficking of the chimeric svFv- 
PDGFR-TM is slow due to fused svFv not being a natural membrane protein. 
The expression and trafficking of the mutated hemagglutinin could also be 
impaired due to the modifications introduced;  
• The reduced size of the scFv molecule (~27kDa) could also be a factor specially 
when one considers that the hemagglutinin (~66kDa) molecule is quite large in 
comparison. That could be a factor interfering on the biding capability of the 
scFv; 
• Other members of my work group successfully used a scFv-Her2/neu for virus 
like particle (VLP) re-targeting. I assume that the efficient use of the molecule 
for LV application is a matter of optimization of transfection protocols and 
cloning of the scFv into the pDisplay vector. 
Furthermore, as shown in figure 22, in some cases viruses bearing only a fusogenic 
protein could transduce cells in culture. I can speculate that perhaps the mutations 
introduced in HA were not completely effective. The risk of cross- contamination or 
sample mix up also must be kept in mind.  
Another reason for low efficiency re-targeted LV is the fact that he hemagglutinin 
molecule is natively inactive. Several studies suggest it needs to be activated in order 
to promote efficient fusion (Chaipan et al., 2009) and that the low pH of endosomes in 
the cytoplasm is supposed to promote  HA activation (Gray and Tamm, 1998), (Reed 
et al., 2010), (Reed et al., 2010), (see figure 14). Other studies suggest that pH drop 




active. In the influenza wt virus hemagglutinin is co-expressed with molecules of 
Neuraminidase, which will facilitate the necessary conformational changes in HA 
(Porotto et al., 2012), (Bose et al., 2012). Other studies suggest that hemagglutinin 
can be activated by partial cleavage with the enzyme trypsin (Chaipan et al., 2009). 
Perhaps co-expression of a neuraminidase molecule on re-targeted viral envelope to 
mimic influenza virus fusion function could lead to higher efficiency viruses.  
An option to try and improve re-targeted viruses would be the use of a fusogenic 
molecule other than fuHA. Studies suggest the use of Sindbis virus glycoprotein (Lei 
et al., 2009) and glycoproteins from Henipavirus genus (Khetawat and Broder, 2010) 
among others as fusogenic molecules. 
There are also ways of improving virus efficiency such as the use of certain chemicals 
during viral production and transduction. 
In this study I used a protocol that incorporate an 8h incubation with sodium butyrate 
with the intent to boost the protein expression by the producer cell line. This chemical 
is believed to be a non-specific histone deacetylase (HDAC) inhibitor, therefore 
improving the accessibility of some genomic areas to polymerase complexes (Chen et 
al., 1997), (Govindarajan et al., 2011). Since we mostly produced LV carrying 
fluorescent reporters, we could analyse transfection efficiency during viral production 
and could observe a boost in fluorescence intensity on transfected cells after 
incubation with sodium butyrate.  
The use of cationic polymers like polybrene during cell transduction is also a validated 
way of increase the efficiency of viral transduction (Davis et al., 2002). The claimed 
mechanism is the decrease of repulsion charges between the cell membrane and the 
viral envelope, facilitating viral-cell biding. However, the method is not without flaws for 
studies suggest cytotoxicity mesenchymal stem cells (Lin et al., 2011). 
4.4.1. The influence of the tetraspanin CD9 on LV efficiency 
 
In 2018 we published a study in which there is evidence of improved LV upon co-
expression of CD9 and VSV-G  on lentiviral envelope (figure 23) (Böker et al., 2018). 
There are some possible explanations for that: 
• Since CD9 alone was also shown to be able to promote binding and fusion of 




co-expression of CD9 with other targeting molecules would have a synergistic 
effect;  
• The postulated role of CD9 in cell adhesion (Reyes et al., 2018), (Leung et al., 
2011) could make up for a somewhat more “adherent” viral envelope, increasing 
virus-cell binding successes.  
As an extension of that study, we sought to assess the impact of CD9 on Rabies-G 
pseudotyped LV. We produced LV-Rabies-G and LV-Rabies-G-CD9, determined 
physical titer and analysed the transduction patterns on four different cell lines. Figure 
24 shows four technical replicas of ELISA tittering comparing both viruses. There was 
no significant change in the number of virus produced, as observed on LV-VSV-G-
CD9. However, unlike previously observed there was no quantifiable change on the 
transduction patterns of LV-Rabies-G-CD9 when compared to LV-Rabies-G (figure 
25). So far two different batches of LV-Rabies-G-CD9 were produced and tested. The 
first one led to inconclusive results (very low transduction efficiency). Transduction 
patterns were analysed 72h after addition of 150 MOI LV. Perhaps the amounts of virus 
used for transduction need to be optimized, or the synergistic effect of CD9+Rabies-G 
takes longer to happen.   
As future steps on working with improving LV, I would like to go deeper in the 
investigation of the effects of the CD9 molecule on viral efficiency. I would propose 
using the CD9 tetraspanin as an anchor for an scFv rather than the PDGFR from 
pDisplay vector. Perhaps there will also be a synergistic effect there while the 
expression of a chimeric CD9 protein could mask its inherent targeting property. 
4.5. Genetic manipulation tools 
 
In this study we focused on the development of targeted tools for gene delivery that 
are more specific and efficient. We produced pseudotyped LV that were able to deliver 
fluorescent reporters. Here we show applications of different genetic manipulation tools 
that can be used in combination with our LV system. 
4.5.1. Gene expression manipulation with the CRISPR-Cas9 system 
 
Since its discovery in 1993 till its adaptation for use in eukaryotes 20 years later by 
Zhang and collaborators (Cong et al., 2013), the CRISPR system is nowadays a very 




Researchers worldwide have been working to improve the system and get rid of its 
disadvantages, such as the off-target effects and the potential immune response 
triggered by the Cas9 in humans. For an overview on improvements and new 
applications of the CRISPR system see (Adli, 2018). 
The ability of manipulating the genes on a genomic level open several possibilities 
specially regarding genetic disorders. Being able to correct a gene that is 
malfunctioning, either by disrupting or enhancing its expression shines a new light into 
the lives of patients that otherwise are condemned to an incurable genetic disease.  
For the research area the possibilities are also astonishing. Changing a cell fate by 
manipulating a pool of genes at the same time open many exciting possibilities. Some 
of these possibilities are also frightening, as proofed by the recent announcement of 
the first CRISPR babies created by a Chinese scientist. It opens new ethical and 
philosophical discussions for the next generation of scientists, me included. 
In this thesis I was able to utilise the classical CRISPR-Cas9 system to disrupt GFP 
expression on GFP expressing HEK293 and SH-SY5Y (figure 27). We produced LV-
VSV-G carrying components of the system to produce cell lines stabling expressing 
Cas9 (HEK293-Cas9 and SH-SY5Y-Cas9) and dCas9 (HEK293-dCas9) and sgRNA 
expression construct to disrupt GFP expression in Cas9 cells.  
The CRISPRi and CRISPRa systems are cleaver and useful developments of the 
technology. CRISPRi in particular is an interesting approach on gene expression 
knocking-down (Gilbert et al., 2014), (Gilbert et al., 2013), (Qi et al., 2013) that leads 
to a lowered expression of a target mRNA rather than a modulation of mRNA activity 
like the RNAi systems, what is handy when studying function of new molecules. 
In the future I would test the CRISPRi system to disrupt the expression of CRLF3 as 
an additional gene expression repression method together with RNAi system.  
4.5.2. RNAi application to uncover the function of CRLF3 
 
The cytokine receptor-like factor 3 is a mysterious molecule that we showed is 
expressed in several cell lines, including neuroblastoma and is scarcely expressed in 
breast and cervical cancer derived cell lines (figure 30).  
The group of Dr. Ralf Heinrich already unravelled an important role of the orthologue 




That is quite an important role for a molecule we barely know anything about its 
orthologue in mammalians.  
The fact that it plays a role in cell protection and it appears to be down-regulated in 
cancer cell lines brings the question if this is a kind of defence mechanism of the cell 
upon harmful physiological changes caused by cancerous stimuli. A lower number of 
receptors would lead to higher chances of apoptosis and consequent elimination of the 
cancerous cell. However, they survive and proliferate better than normal cells. 
It is a very interesting scientific question to investigate whether the effects observed in 
invertebrates are translated to mammalian cells. If that holds true, we can be on the 
verge of uncovering a new potential therapeutic target for diseases that cause 
neurodegeneration and cancer. There can also be ways we can use our new 
understanding of this molecule to develop treatments to prevent and treat brain injuries 
such as brain ischemia and trauma.  
In this study we show that we can successfully manipulate the expression of CRLF3 
using our LV tool and shRNA constructs. The next step is issuing what happens to 
cells under harmful stimuli when the expression of the receptor changes. For that we 
need to establish an efficient way of quantifying cellular damage so we can analyse 
the influence of Epo and its interaction with CRLF3 under harmful stimuli such as 
hypoxia and chemical damage.  
4.5.3. Genetic manipulation at a post-transcriptional level: untangling the 
biology of a snoRNA 
 
The field of RNA biology is one of the most exciting and full of possibilities in molecular 
biology in my opinion. New classes of RNA are discovered quite often, and their 
function remains a mystery or turn out to be fascinating new tools that open unexpected 
technologies, e.g. RNA interference or genome editing with the CRISPR/Cas9 system.  
Gone is the time that science considered non-coding RNA (ncRNA) cellular garbage. 
We learn more every day about the importance of these volatile molecules and their 
intricate regulatory functions and complex interactions (Karapetyan et al., 2013), 
(Vance and Ponting, 2014), (Quan et al., 2017). 
During this study I had the opportunity to scratch the surface of this giant iceberg that 




The U3 snoRNA is not less mysterious. Before thought to be exclusively in the nucleus 
where it performed its function at early rRNA cleavage (Cléry et al., 2007), studies 
showed that this molecule could leave the nucleus and give origin to miRNA (Ender et 
al., 2008), (Brameier et al., 2011).  
Dr. Nicolás Lemus during his PhD studies analysed NGS data from RNA-protein and 
RNA-RNA interactions, he showed that U3 was possibly interacting with protein miRNA 
processing machinery such as the cytosolic Dicer. On that course also a possible 
mRNA target (SNX27) for miR-U3 was identified. Using a newly developed flow-
cytometry based technique to analyse miRNA activity at single cell level, it was also 
observed that U3 behaves like a low functional miRNA (figure 7) (Lemus-Diaz, 2017). 
In this study I showed my small contribution to this project. By isolating RNA from nuclei 
and cytoplasm of cells lacking Dicer, we could show that U3 is indeed also present in 
the cytoplasm and in higher amounts when Dicer is depleted (figure 31). By utilizing 
an LNA-miRNA q PCR detection kit we could detect miR-U3 and show that possibly its 
biogenesis is Drosha independent, once it’s still expressed even in higher amounts in 
cells that lack this protein in the nuclei (figure 32 and 33). We also show that when 
Dicer is not present, miR-U3 expression is also absent, which reinforces the theory 
that U3 interacts with Dicer like a classical miRNA. 
For the future we still need to confirm the Dicer interaction by rescuing its expression 
in Dicer-KO cells (Kanellopoulou et al., 2005), (JnBaptiste et al., 2017) and observe 




In this thesis, I demonstrate the successful establishment of the techniques to 
pseudotype and re-target HIV-1 based LV that can deliver a variety of GOI to a variety 
of mammalian cell lines, dissociated neuronal cultures and organotypic non-human 
primates brain slices: 
• Fluorescent reporters 





I also showed here that combining the genome manipulation techniques and the 
delivery tools I have mastered during this project and used these to investigate the 
function of a receptor that might turn out to be a potential target for cancer and neuro 
therapies. Furthermore, I contributed substantially in a study that demonstrates how 
snoRNAs can derive functional miRNA and the project summarizing the biochemical 
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5.3. Plasmid maps: constructs obtained from other sources 
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